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Abstract

Eosinophilic esophagitis (EoE) is a rare immune-mediated illness with symptoms that range from
difficulty swallowing to food impaction of the esophagus. Most published studies have been documented
among patients residing in cool regions with significant annual rainfall. No published studies to our
knowledge have been performed examining the healthcare utilization trends of EoE in Nevada. Utilizing
two unique databases, the factors associated with EoE healthcare utilization patterns in Nevada were
examined. All analyses were performed in R version 3.5.1. This study included a demographic and
regional analysis identifying risk factors associated with having an EoE healthcare visit in Nevada.
Several trends complemented those seen in other EoE studies including increased utilization among male
and pediatric subgroups, as well as those of Caucasian descent. In the second part of the study, clinical
EoE comorbidities among subgroups were identified. While this disease typically has a well-documented
relationship with atopic illness, the comorbidities identified in Nevada were largely gastric in nature;
indicating a trend of late-stage diagnoses of the disease. Treatment by region differed significantly,
pointing to a lack of consistency of EoE knowledge among healthcare providers. Data from a small cohort
of EoE positive pediatric patients from a local clinic (n=59) were also obtained. This clinical EoE subset
was used to complement the hospital utilization database in order to identify common sensitization
patterns among the pediatric population. Surprisingly, this population was largely sensitized to
aeroallergens, as opposed to the common food allergens reported in the literature. This indicates that
treatment approaches for this condition in Nevada may be unique to those found in other regions. The
final part of this study examined the financial impact of EoE healthcare utilization in Nevada. The cost of
EoE was significantly greater for the pediatric subgroup as well as those receiving treatment in the
Southern Nevada region. Lastly, in order to gain a better understanding of cost relative to similar chronic
inflammatory diseases, a comparison was performed between EoE, Crohn’s disease and Celiac disease.
Significant differences in cost and utilization patterns existed by gender, age and healthcare setting.
Findings from this study fill an important gap in EoE knowledge in this region. Improved physician and
iii

public health education for treatment is critical as the sensitization patterns in Nevada appear unique
relative to other regions. Early identification of EoE diagnosis may improve knowledge and treatment
among patients and providers in Nevada.
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Chapter 1: Background Literature Review of Eosinophilic Esophagitis
1.1 Eosinophilic Esophagitis
Eosinophilic Esophagitis (EoE) was first described as a rare chronic condition in 1978 (Landres,
Kuster, & Strum, 1978). In less than 50 years, this disease has progressed from a rare case-reportable
condition to a disease commonly observed in emergency rooms and endoscopy centers in Western
populations (Dellon & Hirano, 2018; Prasad et al., 2011). Eosinophilic esophagitis is an immunemediated allergic disease characterized by a dysfunctional esophagus and the presence of > 15
eosinophils per high-power field (HPF) in the esophageal mucosa on esophageal biopsy (Dellon &
Hirano, 2018; Longitudinal, Structural, & Models, 2015). Treatment options are limited, and several risk
factors increase the odds of developing EoE. The most common hypothesis that describe the increased
incidence includes an increase in atopic diseases such as asthma, atopic dermatitis, allergic rhinitis, and
food allergies observed in Western populations (Dellon, 2014). This disease is becoming increasingly
recognized, due to both increased incidence and improved detection methods, however, many questions
remain unanswered (Kerlin, Jones, Remedios, & Campbell, 2007).
1.2 Clinical Presentation of the Disease
Eosinophilic esophagitis can present at any age, but tends to be male predominant and is most
common in Caucasian patients compared to other races (Dellon, 2014). Clinical presentation of EoE is
different in children and adults. In children, a failure to thrive is observed due to feeding intolerance,
abdominal pain, food impactions, and vomiting (Ishimura et al., 2015). In adult patients, dominant
symptoms include difficulty swallowing, food impaction, heartburn, and chest pain (Ishimura et al.,
2015). In extreme cases food impaction can require a visit to the emergency room for an urgent
endoscopy (Dellon, 2014). Eosinophilic esophagitis is one of the most frequent diseases identified as the
cause of food impaction in emergency departments across the United States (Dellon, 2014). One study
states that 46-63% of patients experiencing food impaction, or difficulty swallowing will ultimately
receive a diagnosis of EoE (Dellon, 2014).
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1.3 Diagnosis and Pharmacotherapy
Diagnosis of EoE is determined using several approaches. If a patient previously diagnosed with
gastroesophageal reflux disease (GERD) receives proton pump inhibitor (PPI) treatments that result in no
response, EoE is suspected and an endoscopy is performed (Ishimura et al., 2015). During the endoscopy,
certain phenotypic findings can allude to EoE, including esophageal rings, commonly known as “feline”
esophagus, where food impaction or rupture typically occurs (Hawari & Pasricha, 2007; Ishimura et al.,
2015). A biopsy is performed during the endoscopy; an EoE diagnosis is made if there are >15
eosinophils/HPF in the biopsy (Ishimura et al., 2015). If the patient is not already on therapy for
gastroesophageal reflux, the patient is introduced to a PPI treatment. If therapy results in improvement of
symptoms and <15 eos/hpf, then it is termed “PPI-responsive esophageal eosinophilia” and PPI therapy is
used as ongoing treatment (D’Alessandro, 2015). If the PPI treatment does not garner a response and the
eosinophilia is persistent, the patient is diagnosed with “PPI unresponsive EoE” and put on a steroid
regimen, or a specific elimination diet (D’Alessandro, 2015).
Adults are put on a selective food elimination diet by a gastroenterologist and expected to follow
the recommendations with little to no guidance. In pediatric patients, determining which food is an
allergenic culprit is priority. This allows for less nutritional deficiency and growth failure, which may
happen in young children placed on a broadly restrictive diet (Spergel et al., 2009). Allergenic foods may
be determined by either skin testing, patch testing, and/or individual removal of each food. Adult and
pediatric patients are expected to remain on the elimination diet for life after the disease enters remission
stages. If neither PPI or elimination diet result in a reduction of symptoms of EoE, the patient is placed on
an inhalational topical steroid to reduce swelling (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017).
Since this is a chronic disease with no cure, relapse most often occurs when patients discontinue drug
therapy, or deviate from the prescribed elimination diet (Davis, 2018).
1.4 Pathophysiology
The pathophysiology and etiology of the disease are not well-understood; therefore, studies
present various hypotheses. Current hypotheses regarding the etiology of EoE include a possible familial
2

inheritance pattern. In addition, damage to the epithelial layer of the esophagus via acid reflux may
increase the danger of developing EoE. This damage may allow the inappropriate contact of either a food
or aeroallergen to the mucosal layer of the esophagus initiating an allergenic response; which is normally
prevented by the epithelial barrier covering the luminal surface of the esophagus (Takashima S, Tanaka F,
Otani K, Hosomi S, Nagami Y, Kamata N, Taira K, Yamagami H, Tanigawa T, Fukumoto S, Watanabe
T, 2019). After this contact an immune mediated response hypothesized to be driven by T helper 2 (TH2
cells) with release of IL-5 is established which results in eosinophil infiltration to the esophagus (Aceves,
2014). TH2 cells also have the capability of producing IL-4 which is responsible for instructing B cells to
isotype switch to allergic antibody IgE production (Thomas M. Runge, MD & Evan S. Dellon, MD,
2017). The eosinophilic infiltration then results in the macroscopic observation of scaring/ring formation
that is noted on endoscopy (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017). Finally, the
microbiome and early use of antibiotics is a newer hypothesis, proposing that children on long-term
antibiotic regimens lose a significant portion of gut bacteria that may help regulate allergic diseases
associated with EoE (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017). These hypotheses continue
to be investigated in the gastroenterology and immunology fields as the mechanistic effects of EoE are
understood.
1.5 Risk factors
Several risk factors exist for developing EoE including gender, race, preexisting allergies, season,
and climate (Dellon, 2014). In a retrospective study performed at the University of North Carolina by
Sperry et al., 208 EoE records were identified and stratified by race and gender (Sperry, Woosley,
Shaheen, & Dellon, 2015). The mean age was 25.7 yrs. and the participants spanned from 6 months to 78
years, with 50% of the individuals under the age of 18 (Sperry et al., 2015). Of the 208 records identified,
76% were male and 82% were Caucasian, which aligns with other population studies performed
(Iwanczak et al., 2011; Longitudinal et al., 2015; Molina-Infante et al., 2018; Warners et al., 2018).
While there are reported differences between gender and race, the reason for this is unknown (Sperry et
al., 2015). Additionally, there are typically no significant differences in endoscopy findings or
3

symptomology between adult males and females, or among different races/ethnicities diagnosed with EoE
(Sperry et al., 2015).
Food and aeroallergens tend to exacerbate the symptoms of EoE. The most common food
allergens reported are milk, eggs, soy, wheat, beef, and rye (Durrani, Mukkada, & Guilbert, 2018; Nielsen
& Husby, 2007). Other studies argue that aeroallergens are to blame for the development and
symptomology of EoE. Armentia et al. identified 129 EoE adult patients who agreed to skin-prick tests
for various aeroallergens (Armentia et al., 2018). Grass was identified as the predominant aeroallergen in
the group, specifically Bermuda in 36.4% of cases and rye grasses in 27.1% of cases (Armentia et al.,
2018) Several tree pollens contributed as well, including pollen from olive trees in 17.1% of cases and
peach trees in 11.6% of cases, were identified as triggers of EoE symptoms (Armentia et al., 2018).
Regional and seasonal variation of EoE is also present in many studies (Hurrell, Genta, & Dellon,
2012; Iwanczak et al., 2011). Typically, the prevalence of EoE is higher in Northeastern and urban areas,
as well as in cold and dry zones (Hurrell et al., 2012; Longitudinal et al., 2015). Wang et al. reports that
significantly fewer new EoE patients are diagnosed in winter (17.9% of cases diagnosed) compared to fall
(24.8% of cases diagnosed), spring (27.8% of cases diagnosed), and summer (29.5% of cases diagnosed)
(Wang, Gupta, & Fitzgerald, 2007). In a study performed by Almansa et al., the same pattern was
identified. Significant increases of EoE patients were seen in spring and summer months (68.3% of cases
diagnosed; <0.001) when compared to fall and winter months (31.7% of cases diagnosed; 0.019)
(Almansa et al., 2009).
1.6 Genetic Components of the Disease
While this is not the focus of this study, weak evidence exists of potential genetic links. Martin et
al. reports that EoE susceptibility may exist due to synergistic interactions between genetic loci: thymic
stromal lymphopoietin (TSLP) and calpain 14 (CAPN14) (Martin et al., 2017). This study alludes to
potential research that could aid in identifying patient-specific therapeutics, or could help predict EoE
susceptibility (Martin et al., 2017).
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Due to the rare nature of the disease it is currently unknown whether there is a family history
component. Some studies indicate that if a family history of atopy or eosinophilic diseases exists, then
risk of EoE may be increased (Sorser, Barawi, Hagglund, Almojaned, & Lyons, 2013). Other studies
report using whole genome sequencing to identify possible genes that may contribute to the development
of EoE in adult and pediatric patients (Thomas M. Runge, MD & Evan S. Dellon, MD, 2017). Finally,
several genetic/inherited connective tissue disorders have been associated with EoE, including LoeytDietz syndrome (LDS), Marfan syndrome type II, and Ehlers-Danlos syndrome (Davis, 2018).
1.7 Comorbidities
The most well-described comorbidities for EoE include atopic disorders such as asthma, allergic
rhinitis, and atopic dermatitis, to name a few (Mohammad et al., 2017). Eosinophilic esophagitis is an
immune-mediated disease, therefore, the presence of other allergic disorders mediated by
immunoglobulin E (IgE) is possible. The presence of these diseases may exacerbate the symptoms of
EoE. Studies report that 50-80% of patients diagnosed with EoE have a history of atopic illness (Ridolo et
al., 2012). In a single-site study of 449 patients, Mohammad et al. reports that 77.5% (n = 348) of
patients with EoE in the United States suffer from at least one atopic comorbidity (Mohammad et al.,
2017). Allergic rhinitis was prevalent in 61.9% of the EoE population, followed by asthma (39.0%), and
atopic dermatitis (46.1%) (Mohammad et al., 2017).
Interestingly, a study performed in Australia identified a dichotomy between food and inhalant
allergens using patch testing (on n = 33/45 EoE positive patients) and skin prick tests (on n = 45/45 EoE
positive patients) (Sugnanam et al., 2007). Younger patients showed an increased IgE when exposed to
food patch testing, while older patients showed a higher sensitization to inhalant allergens (Sugnanam et
al., 2007). In Midwestern Spain, rhinoconjunctivitis (62%), asthma (52%), and food allergies (23%) were
among the highest reported comorbidities in patients with EoE (Molina-Infante et al., 2018).
1.8 Rates Reported Internationally and Nationally
Countries such as Poland, the Netherlands, Spain, Egypt, Japan, and the United States have
published large scale population studies and exposed many common factors about the disease (Fouad,
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Fouad, Mokareb, Mohamed, & Abdel-Rehim, 2018; Ishimura & Kinoshita, 2018; Iwanczak et al., 2011;
Molina-Infante et al., 2018; Warners et al., 2018).
A 5-year pediatric patient study in Poland identified 84 records (23.8% female and 76.2% male)
of EoE across ten gastroenterology centers in pediatric patients who had undergone esophageal
endoscopies (n = 35,631) (Iwanczak et al., 2011). The most frequent symptoms of EoE in the patients
included feeding aversion, regurgitation or vomiting, abdominal pain, dysphagia, and chest pain
(Iwanczak et al., 2011). Further, EoE was diagnosed in all pediatric ages (1-18 years) mainly during the
spring (45.2% of cases diagnosed) and summer (28.5% of cases diagnosed) (Iwanczak et al., 2011).
The Netherlands reports a rapid increase in EoE over the past 20 years. In a single-site study of
the Dutch pathology registry, 5,080 records of EoE out of 11,288 endoscopy records were described
(Warners et al., 2018). The incidence of EoE had increased nearly 200-fold from 1996 to 2015
(0.01/100,000; 95% CI: 0.00-0.02 to 2.07/100,000; 95% CI: 2.05-2.23), whereas the endoscopy rates had
only tripled in the same timeframe (Warners et al., 2018). No seasonal variation was noted, however,
incidence was higher in males than females (3.02/100,000; 95% CI: 2.66-3.41 versus 1.14/100,000; 95%
CI: 0.93-1.38, respectively) and higher in adults than children (2.23/100,000; 95% CI: 1.99-2.49 and
1.46/100,000; 95% CI: 1.09-1.91, respectively) (Warners et al., 2018).
Spain also reports increased incidence in EoE over the past decade. In a large EoE geographical
study in Midwestern Spain, 196,363 medical records were examined and newly diagnosed adult EoE
cases between January 1, 2007 through December 31, 2016 were recorded (Molina-Infante et al., 2018).
The annual incidence of EoE increased from 2.97/100,000 in 2007 to 13.72/100,000 in 2016 (MolinaInfante et al., 2018). Molina-Infante et al. (2017) did not report seasonal variation or race/ethnicity
differences, but did report that incidence was significantly higher in males (73% of cases diagnosed) than
females (27% of cases diagnosed) (Molina-Infante et al., 2018).
Contrary to Poland, the Netherlands, and Spain, studies from Egypt and Japan report lower
incidence rates. In a single-center, cross-sectional study conducted in Egypt from 2013-2015, 476 adult
patients with upper gastrointestinal symptoms underwent endoscopies (Fouad et al., 2018). Of those
6

observed patients, only four (1.87%) had a diagnosis of EoE (Fouad et al., 2018). Additionally, in Japan,
a study was performed in 2010 that examined medical records of patients who had undergone an upper
gastrointestinal endoscopy (n = 23,346); of those patients only four were diagnosed with EoE (Ishimura
& Kinoshita, 2018). In 2017, using identical criteria, a follow-up multi-center prospective study was
performed (n = 17,324), of those, eight individuals were diagnosed with EoE (Ishimura & Kinoshita,
2018). While the rates were lower, the EoE diagnosed male to female ratio (4 male:1 female) was similar
to other studies performed (Ishimura & Kinoshita, 2018).
Although there was a slight increase in incidence of EoE in the clinics observed in Japan, the
rates are still much lower than those in Western populations (Ishimura & Kinoshita, 2018). Several
studies note a difference of EoE incidence and symptomology in Asian populations when compared to
Caucasian populations (Ishimura et al., 2015; Ito, Fujiwara, Kojima, & Nomura, 2015). A possible reason
includes the difference in diet between the two populations. The Food and Agriculture Organization of the
United Nations reports the total vegetable supply in Eastern Asia is more than double what is distributed
in North America, while the exact opposite is true for the total meat supply (Ito et al., 2015).
Several EoE studies have been published in the United States. A nationwide retrospective study
on 26 major healthcare systems was performed using a commercial database (Longitudinal et al., 2015).
Over 30 million individual, adult medical records were examined and the report contained 7,840
individual records with a diagnosis of EoE from 2010-2015 (25.9/100,000; 95% CI: 25.3-26.5)
(Longitudinal et al., 2015). A majority of the records were male (61.9% of records), Caucasian (89.3% of
records), and ages ranged from 18-65 years (Longitudinal et al., 2015). Hurrell et al. (2012) examined
seasonal variation in the United States using the Köppen-Geiger climate zones, which stratifies zip codes
into main climate type A – tropical, B – arid, C – temperate, D – cold, E – polar (Hurrell et al., 2012).
Results showed that the odds of developing EoE are 39% higher in cold (D) climate zones (OR = 1.39;
95% CI: 1.34-1.47) compared to the tropical zones (OR = 0.87; 95% CI: 0.71-10.8) (Hurrell et al., 2012).
Finally, Davis (2018) reports that EoE is most commonly found in rural and suburban areas when
compared to metropolitan areas (Davis, 2018).
7

1.9 Overall Impact of EoE
While the effects of EoE on the adult and pediatric populations has been well studied, the cost of
EoE is seldom reported. One study used the IMS LifeLink® PharMetrics Health Plan Claims Database to
examine the healthcare utilization and costs of EoE in the United States (Jensen, Kappelman, Martin, &
Dellon, 2015). Median costs for EoE included ~$2,000 for outpatient visits, ~$150 per endoscopic
treatment, and ~$300 per pharmacy claim for PPI medication (Jensen et al., 2015). The overall prevalence
estimate for the US was between $503 million to $1.4 billion per year, depending on the treatment,
procedures performed, and hospital setting utilized by the patient (Dellon, Jensen, Martin, Shaheen, &
Kappelman, 2015).
Several studies have identified negative quality of life (QoL) impacts from eosinophilic
esophagitis in both adult and pediatric patients. In a multi-center cross-sectional study, Lucendo et al.
used the Adult Eosinophilic Esophagitis Quality of Life (EoE-QoL-A) questionnaire to identify and
quantify determinant factors of health-related QoL in EoE patients (Lucendo, Arias-González, MolinaInfante, & Arias, 2017). The total response was n = 170 and was predominantly male (73.5%) (Lucendo
et al., 2017). Disease anxiety (2.13 + 0.9 points), choking anxiety (1.97 + 1.1 points), social impacts from
EoE (1.77 + 1.1 points), and diet/eating impacts (1.68 + 0.9 points) exhibited the highest mean scores and
were the most important factors, whereas emotional impact had the lowest mean score (1.15 + 0.9) on the
questionnaire (Lucendo et al., 2017). In a cross-sectional study performed in the United Kingdom, the
Short Form-36 (SF-36) questionnaire was utilized for adult EoE patients (n = 88 total; 44 EoE patients; 44
matched controls) (Hewett et al., 2017). Patients who took the SF-36 questionnaire had higher rates of
antihistamine and steroid use than controls and patients with EoE reported a statistically significant lower
mental QoL (Hewett et al., 2017).
The pediatric population is also significantly affected by EoE. A group of pediatric patients was
examined (n = 35, mean was 10 years old) and reported vomiting (71.4% of cases) and abdominal pain
(51.4% of cases) as the top symptoms experienced (Rodrigues Mariano De Almeida Rezende et al.,
2014). While many of the children were aware of the disease and maintained a good nutritional state
8

(82.8% of cases), over two-thirds of the population exhibited food allergies or pollen sensitivities
(Rodrigues Mariano De Almeida Rezende et al., 2014). The pediatric patients treated in this study did not
exhibit alterations in growth curves, which aligns with other pediatric studies performed overseas
(Rodrigues Mariano De Almeida Rezende et al., 2014). This is likely due to disease isolation in the
esophagus (Rodrigues Mariano De Almeida Rezende et al., 2014). Unfortunately, the same cannot be
said for the psychosocial aspects of pediatric patients diagnosed with EoE. Franciosi et al. (2012)
conducted focus interviews on EoE children from 2-18 years old and the respective parents in an attempt
to identify concerns related to EoE-specific health related QoL (Franciosi et al., 2012). The concerns of
the parents included “worry about symptoms and illness” as well as diet and medication adherence,
whereas the pediatric patients were more concerned with “being different that family and peers” as well
as difficulties eating food (Franciosi et al., 2012).
1.10 Eosinophilic Esophagitis in Nevada
This dissertation presents an extensive literature review, alongside epidemiological methods and
various statistical testing to describe the EoE population in the state of Nevada. To our knowledge, no
published studies have been performed that examine eosinophilic esophagitis in the state of Nevada.
Therefore, the studies presented here sought to fill several gaps in the literature and covers several
objectives. In Chapter 2 the distribution of EoE in Nevada and the risk factors associated with this disease
in the state is described. Chapter 3 discusses the comorbidities associated with EoE in relation to
demographic subgroups. Additionally, in Chapter 3, a histologically positive pediatric EoE clinical subset
was provided by University of Nevada, Reno School of Medicine (UNR SOM) to help determine aeroand food sensitizations in the pediatric EoE population. Finally, in Chapter 4, the cost of healthcare
utilization of EoE diagnosed adult and pediatric records was examined using service, procedure, and
diagnosis codes. These results were compared to two well-known inflammatory conditions to put the
impact of EoE into context. Finally, a summary of the findings described, and public health implications
are presented in Chapter 5.
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1.11 Summary of Database and Ethical Considerations
Data for the studies presented in Chapters 2 – 4 were provided by the Center for Health
Information Analysis (CHIA) for Nevada. This center holds comprehensive health care data records for
all causes from multiple healthcare settings in the state including: ambulatory surgery centers (ASC),
emergency departments (ED), inpatient centers (IP), and other outpatient settings (THOS) and is Health
Insurance Portability and Accountability Act (HIPPA) compliant. These datasets contained over 300
variables and were thus reduced to include only the necessary variables. Each set of variables used are
described in each study chapter. The codebook produced for these studies is included in Appendix A.
Prior to the start of the study a Limited Data Set Use Agreement (LDSUA) was approved and
subsequently signed by all parties participating in the project. The LDSUA is provided in Appendix B.
This project, and all subsequent studies in this dissertation, were deemed exempt for secondary data
analysis by the UNLV Office of Research Integrity Human Subjects Board due to the de-identified nature
of the data on June 19th, 2018.
The approval process and description of the clinical dataset provided by UNR SOM is presented
in Chapter 3 and the approval documentation is presented in Appendix C.
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Chapter 2: Factors Associated with Eosinophilic Esophagitis in Nevada

Abstract
Eosinophilic esophagitis (EoE) is a rare disease not well-characterized in the state of Nevada.
Five-years of hospital utilization data (2013-2017) yielded over 2,000 EoE records across all hospital
settings. Multiple logistic regression was utilized to determine factors associated with an EoE visit in
Nevada. Males were 2.93 times more likely (95% CI: 2.53, 3.41; P < 0.001) to have an EoE visit when
compared to females. Older age was a significant factor; for each additional year in age the odds of
having an EoE visit increased by 30% (Odds ratio (OR) = 1.30, 95% CI: 1.28, 1.31; P < 0.001). Admit
year was also significant; records in 2016 had 26% higher chance of an EoE event when compared to
records in 2013 (OR = 1.26, 95% CI: 0.99, 1.59, P = 0.05). Overall, race was not a significant factor (P >
0.05). Most interestingly, individuals living in the Northern region of Nevada have 1.95 higher odds of an
EoE visit than their Southern counterparts (OR = 1.95, 95% CI: 1.68, 2.26; P < 0.001). This study seeks
to improve the understanding of the factors associated with the healthcare utilization pattern of this rare
condition in Nevada.
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Introduction
Eosinophilic esophagitis (EoE) is a rare immune-mediated illness diagnosed histologically via
endoscopy (>15 eosinophils/high-power field) (1, 2). In adults, symptoms arise in the form of persistent
heartburn, difficulty swallowing, and food impaction; among the pediatric population, symptoms often
include: vomiting, nausea, abdominal pain, failure to thrive and, more rarely, food impaction (Spergel et
al., 2009). Current literature indicates that this global disease affects males two times more often than
females and individuals of Caucasian descent are at greater risk compared to other racial groups (3, 4).
Several regional and climate studies performed in the United States characterize the EoE
population; the most notable include studies performed Dellon et al. (2014) and Hurrell et al. (2012).
Dellon et al. (2014) reports the prevalence of EoE as 56.3/100,000 persons, with the highest prevalence
located in the Midwest (33.6/100,000 persons) and the South (32.1/100,000 persons), followed by the
East (19.1/100,000 persons), and the West (15.2/100,000 persons) (Dellon, Jensen, et al., 2015).
Additionally, a climate study performed by Hurrell et al. (2012), reports that the odds of developing EoE
is 39.0% higher (OR = 1.39; 95% CI: 1.34, 1.47) in cold zones, 27.0% higher in arid zones (OR = 1.27;
95% CI: 1.19, 1.36), and lowest in tropical zones (OR = 0.87; 95% CI: 0.71, 1.08) when compared to
temperate regions (Hurrell et al., 2012). Given the published regional and climate results, a higher than
expected number of EoE records were identified in Nevada (n = 2,296) over five years (2013-2017).
Given the relationship between EoE and atopic disease, it is pertinent that region is considered a
factor in this study (Moawad et al., 2010). The state of Nevada is unique in that the federal government
owns nearly 85% of the land, the climate is hot and dry year-round, and the two largest cities (Reno and
Las Vegas) have been named the “Driest Cities in the United States” for several years (6, 7). Patel et al.,
examined five pollen collection sites in the city of Las Vegas, Nevada and concluded that significant
composition and concentrations of pollen existed at all five sites (Patel et al., 2018). Using this
knowledge, it is reasonable to assume that different climatic regions of the state would also exhibit
different allergens year-round, potentially increasing the risk of an EoE event in specific locations.
Further, the Northern region of the state experiences colder than average temperatures in the winter
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(January 25oF/-3.9oC) and summer (July 58oF/14oC) when compared to the Southern region (January
39oF/-3.8oC and July 81oF/27oC, respectively), which could indicate longer a pollination season in the
Southern region. All such factors may play a critical role in the association of EoE and the Nevadan
population. Objectives of this study include: (1) describing the EoE population in the state of Nevada;
and (2) determining existing patterns of EoE in Nevada by region using a large hospital utilization
database.
Methods
Population
The initial database yielded over 12 million hospital utilization records over five years (20132017) for the state of Nevada. Inclusion criteria for selection included healthcare records with primary (1)
through quaternary (4) EoE diagnosis codes (ICD-9 = 530.13 or ICD-10 = K20.0) from all hospital
settings. Only primary through quaternary diagnosis code records were considered “relevant” to the study,
as EoE itself can often be a comorbidity (Durrani et al., 2018). Records were extracted and filtered to
include Nevada residents exclusively, resulting in a total of 2,196 EoE records across all study years and
hospital settings.
Data collection and variable definition
All hospital settings (ASC, ED, IP, and THOS) were merged into one dataset and included the
following variables: patient zip code, race/ethnicity, age, gender, and admit year. The EoE records were
grouped by Northern and Southern regions using zip codes extracted by the statistical software R using
the CRAN “Zip code” package (Breen, 2012). Using the Nevada Governor’s office of Economic
Development, cities located in the Northern Sierra and Northeastern Nevada regions were grouped as
“Northern” and cities located in Central and Southern Nevada regions were grouped as “Southern”
(Nevada Governor’s Office of Economic Development, 2018).
Statistical analysis
Descriptive statistics were performed to identify frequency distributions of the EoE healthcare
utilization population including age, gender, race/ethnicity, admit year, and region. As there was a highly
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unequal distribution of EoE records (n = 2,196) respective to all other possible cause records (n =
12,629,055), a random selection of non-EoE records were selected from the database for comparison; this
allowed for subsequent modeling required to identify significant variables associated with an EoE
healthcare visit. As each dataset by setting type differed in sample size, a 1:5 ratio was obtained using
probability proportionate to size by setting. The sample size of the final dataset (including EoE records)
was 13,079. Multiple logistic regression was subsequently performed to identify the odds of having an
EoE visit versus “other cause” healthcare utilization visit. Demographics and hospital utilization
characteristics were modeled with the dependent variable (EoE) which was coded as binary.
An initial model was run to determine significant univariate variables as well as to avoid
multicollinearity. In the initial logistic regression model, all five variables were significantly associated
with having an EoE visit (region, gender, race, age, and admit year; P < 0.05) and interaction between
region by age as well as region by gender were significant (P < 0.001). The final logistic regression
model included the main effects region, age, gender, race, admit year, as well as region*age, and
region*gender. This was the most parsimonious model identified. Once the final model was selected, the
effect size was determined using follow-up testing. Adjusted odds ratios were generated to identify atrisk factors for EoE healthcare utilization visits in the state of Nevada. Finally, due to the significant
interactions, data were stratified by region to determine differences between demographics and EoE by
region and effect sizes were determined using follow-up testing. Regional odds ratios were calculated to
identify at-risk factors for EoE healthcare utilization visits. A P-value of less than 0.05 and the 95% CI
were set for significance for all models and analyses were run using R version 3.1.5 (R Core Team, 2013).
Results
Statewide and regional demographic analysis
A total of 2,196 EoE records were extracted from the hospital utilization database. The mean age
statewide was 33.2 years old (Standard Error (SE): 0.0017). Records listed as ‘male’ had a higher
representation than females among EoE records (n = 1,398 (63.7%) versus n = 798 (36.3%), respectively)
(Table 1). Table 1 shows that a majority of the EoE statewide records were patients of White/Caucasian
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descent (n = 1,360, 61.9%), followed by 8.58% Hispanic/Other (n = 188), 2.41% of Native American,
Alaskan, Asian or Pacific Islander (n = 53), and Black/African American (n = 99, 4.51%). This
racial/ethnic breakdown was similar to all-cause records.
The total number of EoE records identified in Nevada was 2,196; the total number of records
were similar between the Northern (n = 1,004, 45.7%) and Southern (n = 1,192, 54.3%) regions of the
state (Table 1). The Northern region had a slightly higher mean age at 39.4 years old, whereas the mean
age in the Southern region was lower at 27.8 years old (Table 1). Additionally, records listed as “male”
were 14.6% and 38% higher than records listed as “female” when broken down by Northern and Southern
regions, respectively (Table 1). White/Caucasian was the dominant racial/ethnic group in both regions (n
= 633 (63%) and n = 705 (59.1%), respectively), followed by Hispanic/Other (n = 48 (4.8%) and n = 51
(4.3%), respectively), Native American/Alaskan/Asian/Pacific Islander (n = 23 (2.3%) and n = 40 (3.4%),
respectively), and Black/African American (n = 21 (2.1%) and n = 17 (1.4%), respectively) (Table 1). The
demographic breakdown of the EoE records identified were similar throughout the CHIA database, with
white/Caucasian (61.2%) as the most represented followed by Hispanic/other (11.82%).

Table 1. Demographic Characteristics of Records with an EoE Discharge Diagnosis.
Variable of Interest
Age (mean (SE))
Gender
Female
Male
Race/Ethnicity
Native*
Black/African American
White/Caucasian
Hispanic/Other
Unknown/Missing
Admit Year
2013
2014
2015
2016
2017
*Native

Overall
(n = 2,196)
33.2 (0.46)

Northern
(n = 1,004)
39.4 (0.60)

Southern
(n = 1,192)
27.8 (0.64)

798
1398

36.30%
63.70%

429
575

42.70%
57.30%

369
823

31.00%
69.00%

63
38
1338
99
658

2.87%
1.73%
60.93%
4.51%
29.96%

23
21
633
48
279

2.30%
2.10%
63.00%
4.80%
27.80%

40
17
705
51
379

3.40%
1.40%
59.10%
4.30%
31.80%

357
348
422
531
538

16.26%
15.85%
19.22%
24.18%
24.50%

156
168
194
238
248

15.50%
16.70%
19.30%
23.70%
24.70%

201
180
228
293
290

16.90%
15.10%
19.10%
24.60%
24.30%

group includes: American/Alaskan/Asian/Pacific Islander
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The number of EoE records per admit year across the state increased between 2013-2016 but
decreased slightly in 2017 (Table 1). The records in the Northern region have steadily increased every
year for the last five years (Table 1). The Southern region exhibited a decrease from 2013 to 2014 (1.8%)
but increased continuously from 2014-2016, with a slight decrease from 2016-2017 (Table 1). When the
distribution frequencies of age versus EoE diagnosis level were plotted, primary EoE diagnosis was
heavily skewed to the left. This indicates that pediatric records were the highest reported as a primary
diagnosis between 2013 and 2017.
Statewide analysis
Region, age, gender, race, and admit year were all significant in the final adjusted model (P <
0.05) (Table 2). In follow-up testing those in the Northern region of the state had 1.95 higher odds of
having an EoE visit when compared to their Southern counterparts (OR = 1.95, 95% CI: 1.68, 2.26, P <
0.001) (Table 2). For every year increase in age the odds of an EoE visit increased by 30% (P < 0.001,
95% CI: 1.28, 1.31) (Table 2). Males were 2.93 times (P < 0.001, 95% CI: 1.28, 1.31) more likely than
females to have an EoE visit (Table 2). Due to a small number of records listed as Native
American/Alaskan, or Asian/Pacific Islander race, these racial groups were combined (n = 418). Only the
group labeled “Unknown/Missing” remained significant (P = 0.02) during secondary analysis. It should
be noted that visits with race listed as “Black/African American” had 23% lower odds (P = 0.35, 95% CI:
0.45, 1.32) and those listed as “Non-white Hispanic” had 17% lower odds (P = 0.71, 95% CI: 0.67, 1.31)
of an EoE visit when compared White/Caucasians, although these results were not significant (Table 2).
Finally, the 2016 admit year was significant, with 1.26 higher odds (P = 0.05, 95% CI: 0.99, 1.59) of an
EoE visit when compared to all visits reported in 2013 (Table 2).
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Table 2. Multiple Logistic Regression of Factors Associated with EoE.
Predictor
Region

OR

95% CI

P-value

1.95
*

1.68, 2.26
*

<0.001
*

1.30

1.28, 1.32

<0.001

Female
Male

*
2.93

*
2.53, 3.41

*
<0.001

Native1
Black/African American
White/Caucasian
Hispanic/Other
Unknown/Missing
Admit Year
2013
2014
2015
2016
2017
Interaction Effects
Region*Age
Region*Gender

0.83
0.77
*
0.94
1.22

0.54, 1.29
0.45, 1.32
*
0.67, 1.31
1.04, 1.43

0.41
0.35
*
0.71
0.02

*
1.07
1.11
1.26
1.16

*
0.83, 1.38
0.87, 1.42
0.99, 1.59
0.92, 1.47

*
0.59
0.39
0.05
0.21

Northern
Southern
Age (continuous)
Gender

Race

<0.001
<0.001

1Native

group includes: American/Alaskan/Asian/Pacific Islander
*Reference Group

Regional analysis
Significant interaction effects indicate that logistic regression by region may reveal important
demographic differences. Differences exist between age and EoE by location (P < 0.001). The odds of an
EoE event increase 1.26 times per year in the Northern region (P < 0.001, 95% CI: 1.24, 1.28) and 1.36
times per year in the Southern Region (P < 0.001, 95% CI: 1.33, 1.38) (Table 3). Differences also exist
between gender and EoE by location. Males residing in the Northern region have 2.26 times higher odds
(P < 0.001, 95% CI: 1.84, 2.78) of an EoE event than females residing in the same region. Additionally,
males residing in the Southern region have 3.78 times higher odds (P <0.001, 95% CI: 3.03, 4.71) of an
EoE event than females residing in the same region.
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Table 3. Multiple Logistic Regression of Factors Associated with EoE Stratified by Region.

OR

Northern
95% CI
P-value

OR

Southern
95% CI
P-value

Age (cont.)

1.26

1.24, 1.28

<0.001

1.36

1.33, 1.38

<0.001

Gender
Female

*

*

*

*

*

*

2.26

1.84, 2.78

<0.001

3.78

3.03, 4.71

<0.001

Male

*Reference group

Discussion
Statewide analysis
During analysis, a large sample of the primary EoE diagnoses in the last five years was in the
pediatric age group (>1/3). Secondary analysis indicated that as age increases, the odds of an EoE visit
statewide increased by 1.30 (P < 0.001, 95% CI: 1.28, 1.32), or 30% per year. This could be due to
several factors. First, significant improvements in diagnostic methodologies and identification of this
disease reported in the literature, particularly in the pediatric age group (Spergel et al., 2009). Second,
unique to Nevada, Wong et al. explains that a large percentage of children in the state are sensitized to at
least one outdoor allergen by the age of three (Wong, Wilson, Peele, & Hogan, 2012). Wong hypothesizes
that the unique geographic features of the state may contribute to the heightened percentage of atopic
disease (Wong et al., 2012). These specific geographic factors in Nevada, such as lack of rainfall and
increased atopic disease in young children, could be reasons for the heightened number of records
observed in the state. Consistent with other reports, regional differences were also observed in this study.
Upon further investigation, this finding supports current published data that indicates an increased
prevalence of EoE in colder regions (Davis, 2018). Further geographic and comorbid analysis could help
explain the duality of the atopic diseases and EoE in the state of Nevada.
The records labeled as “males” in the database are nearly double the records labeled as “females,”
which follows current trending reported in the United States and abroad (n = 1,398 (63.7%) versus n =
798 (36.3%), respectively) (4, 13). Males had a higher EoE record representation than females in both the
Northern and Southern regions as well (575 (57.3%) and 823 (69%), respectively) (Table 1). Gender was
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statistically significant in the logistic regression model; males had nearly 3 times higher odds (OR = 2.93,
P < 0.001, 95% CI: 2.53, 3.41) of an EoE visit than females (Table 2). Interaction effects further indicated
that differences exist between EoE and gender by region (P < 0.001) (Table 2). Males in the Northern
region of the state have 2.26 higher odds (P <0.001, 95% CI: 1.84, 2.78) of an EoE event than females
and 3.78 higher odds (P < 0.001, 95% CI: 3.03, 4.71) of an EoE event than females in the Southern
Region (Table 3).
Unfortunately, the results presented here do not allude to the pathological or genetic reasons why
males are more prone to the illness than females, which is largely unknown in the EoE community
(Sperry et al., 2015). The total male records pulled from the CHIA database differed slightly between the
Northern and Southern regions (46.11% and 44.17%, respectively), however not enough to cause the high
odds ratios observed across regions of the state. The literature reports males as upwards of 76% of all EoE
visits reported (Sperry et al., 2015). Moreover, differences between demographics and EoE by region are
also reported throughout the literature. One potential hypotheses for regional differences includes
decreased humidity and rainfall in the western regions, compared to the southern region of the U.S. as
well as increased allergy (Ally, Maydonovitch, Betteridge, Veerappan, & Moawad, 2015).
The most prevalent race included EoE records listed as ‘white/Caucasian’ (n = 1,360, 61.9%),
followed by Hispanic (n = 124, 5.56%), Black/African American (n = 99, 4.51%), and Asian (n = 50,
2.28%). The frequencies reported here are vastly different from other published reports. In a study
performed in Southern California by Kim et al. (2015), the racial/ethnic breakdown of identified EoE
records were much different from Nevada, where Hispanics had higher rates of EoE than any other group.
Kim et al. (2015) reports the percentage breakdown of EoE records in CA as Hispanic (33%),
white/Caucasian (31%), Asian (10%), and black/African American (8%) (Kim, Kim, & Sheikh, 2015).
While according to the United States Census, the white/Caucasian group is dominant in Nevada (49.1%),
a higher number of Hispanic/Latino and Asian records would be expected given the racial/ethnic
composition of the state (United States Census Bureau, 2018). This could point to either a lack of access
in Nevada for specific racial groups, or under/mis-diagnosis of EoE, both which require further in-depth
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analysis. Race was significant in the logistic regression model and indicated that visits with race/ethnicity
listed as “Unknown/Missing” had 1.22 higher odds (P = 0.02, 95% CI: 1.04, 1.43) of having an EoE visit
when compared to white/Caucasian. No further conclusions can be made from this result.
The number of records per year, when compared to all-cause records, continues to increase. The
only statistically significant year in the regression model was 2016, where the odds of an EoE record were
1.26 times more likely than in 2013 (P = 0.05, 95% CI: 0.99, 1.59). While at the significance cutoff, this
variable is importing in understanding the temporal nature of EoE in the state of Nevada. Reports indicate
that the prevalence of EoE is increasing worldwide, both due to improvement of diagnostic techniques,
but also due to the increase in atopic disease (Pawankar, 2014).
Strengths and limitations
The main limitation for this study includes the inability to calculate a true prevalence rate
because the data used does not account for repeat healthcare visits. Finally, a lack of reporting in the
healthcare systems in Nevada was observed during analysis. A significant number of the records provided
do not have a listed race/ethnicity listed but are at a significantly higher risk of an EoE outcome (P <
0.001) (Table 2). Steps should be taken to improve the reporting system in Nevada to avoid this lack of
documentation, particularly when such records indicate significance of a rare disease.
The strengths of this study include a large population size using hospital records as an alternative
to more commonly used self-reported data. Hospital records have more sensitive information that
individuals are not likely to provide in self-report survey situations. The data also represents all setting
types in Nevada, detailing a broader image of the EoE population and the services utilized around the
state. Finally, while the number of records between the Northern and Southern regions was similar, it is
known that the Southern population is nearly double that of the Northern region. Indicating that more
research needs to be done to understand why.
Conclusions and implications
First identified in 1978, this disease is still in its infancy and methodologies are catching up to the
increasing prevalence of the disease (1, 17). To our knowledge, this study is the first of its kind to
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examine the characteristics of the rare disease Eosinophilic Esophagitis in the state of Nevada. The
heightened number of records in pediatric patients over the years, double the representation of males
compared to females, and a high propensity of white/Caucasian records are all widely reported results in
observed EoE populations. However, this study highlights geographic differences for both gender and
age in this population. The effect of region on the EoE population in the state of Nevada, particularly in
those with comorbid atopic disease, is currently unreported in the literature.
Additional studies would add to the developing knowledge base of EoE in Nevada. Studies
examining comorbidities of EoE as well as potential food and aero-allergens would enhance
understanding of this illness both regionally and statewide. Further, identification of important cost
characteristics between pediatric and adult populations may expose gaps in medical care or coverage for
these populations when compared to other immune-mediated diseases.

21

Chapter 3: Comorbidities, Sequela, and Atopic Disease Associated with EoE in Nevada

Abstract
Given the relationship between eosinophilic esophagitis (EoE) and atopy, differences in climate
could significantly impact the presence of this rare immune-mediated disease in select locations. We
aimed to examine the comorbidities and sensitization associated with an EoE diagnosis in Nevada. The
study goal was two-fold: determine the most common EoE comorbidities or sequela in the state of
Nevada using healthcare utilization records; and determine the most common food and aeroallergens in
histologically positive EoE pediatric patients using sensitization data. Esophageal obstruction/stricture
was at the top diagnosis reported in adults with EoE. Among pediatrics, the highest-ranking comorbidities
included asthma, diseases of the stomach, duodenum, and intestine, allergies, and gastroesophageal reflux
disease. Additionally, the top sensitizations reported in histologically positive EoE patients were largely
pollen-related. Atopic disease and food allergen are commonly reported as a comorbid condition with
EoE. In our data aeroallergen sensitization results from histologically positive pediatric EoE patients far
exceeded those of food allergens. Incidences of esophageal stricture/obstruction in adults were also high
indicating late diagnosis. Education about the prevalence of aeroallergen sensitization in this population
may result in earlier diagnoses and help reduce morbidity and cost from this disease.
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Introduction
The prevalence of eosinophilic esophagitis (EoE) continues to increase in parallel with atopic
disease (Davis, 2018). Symptoms vary in adult and pediatric patients, ranging from difficulty swallowing,
food impaction, abdominal pain, and persistent heartburn (Dellon & E.S., 2012). Diagnostic methods for
EoE are invasive and require endoscopic biopsy with the presence of >15 eosinophils per high-power
field (HPF) regardless of age group (Dellon & E.S., 2012). To our knowledge, comorbidities and sequela
associated with EoE in the state of Nevada have not been examined.
In Australia, EoE is often seen in conjunction with allergic rhinitis (93.33% of patients), followed
by asthma, atopic eczema, and anaphylaxis (Sugnanam et al., 2007). Investigators in Brazil reports
allergic rhinitis as the most common comorbidity, identified in 74.2% of EoE cases, with asthma and
atopic dermatitis following closely behind (Rodrigues Mariano De Almeida Rezende et al., 2014). In the
United States, Massachusetts, Ohio, New York, and Illinois studies all reported allergic rhinitis as the
most common comorbidity (70%, 61.9%, and 36%, 58.9%, respectively), followed by food allergies,
asthma, and atopic dermatitis (Fahey, Robinson, Weinberger, Giambrone, & Solomon, 2017; Kagalwalla
et al., 2017; Letner, Farris, Khalili, & Garber, 2018; Mohammad et al., 2017). Illinois also noted allergic
conjunctivitis as a comorbid condition (Kagalwalla et al., 2017).
While food allergies, allergic rhinitis and asthma are relatively common in patients diagnosed
with EoE, food allergens are most often reported. Investigators in Australia and Brazil both reported
cow’s milk allergy in EoE patients (27% of cases and 22.8% of cases, respectively) (Philpott, Nandurkar,
Royce, Thien, & Gibson, 2016; Rodrigues Mariano De Almeida Rezende et al., 2014) (Table 4). In the
United States, a study in Illinois reported the most common food allergen as soy (38.89% of all cases),
whereas studies centered in Ohio, Wisconsin, and New York had higher rates of nut allergies (40.9% of
cases, 51%, and 50% of cases, respectfully) (Fahey et al., 2017; Kagalwalla et al., 2017; Slack et al.,
2013) (Table 4). New York also examined aeroallergen sensitization associated with EoE, where <20% of
records had sensitization to grasses, dust mites, or animal dander. Investigators in Wisconsin identified
native trees (70%) as the dominant aeroallergen (Fahey et al., 2017; Xiwei Zheng, Cong Bi, Marissa
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Brooks, 2015) (Table 4). Finally, Spain reported that individuals with EoE experienced heightened
sensitization to rye (36.4% of patients) and Bermuda grasses (27.1% of cases) (Armentia et al., 2018)
(Table 4).

Table 4. EoE Sensitization Patterns in the Literature.
Reference
(year)
Location
Population

Olson
(2016)
WI*
n = 257

Kagalwalla
(2016)
IL*
n = 78

Weed
Grass1
Tree2
Dust mites
Mold
Dander3

40.0%
55.0%
70.0%
69.0%
46.0%
66.0%

**

Cow milk
Egg white
Soy
Meat4
Seafood
Wheat
Nuts5
Food6

25.0%
21.0%
35.0%

23.6%
33.3%
38.9%

**

**

**

**

17.0%
51.0%

20.8%

**

**

**
**
**
**
**

**

Slack
Fahey
(2016)
(2017)
OH*
NY*
n = 66
n = 38
Aeroallergens
**
66.6%
62.1%
17.0%
59.1%
14.0%
50.0%
17.0%
39.4%
00.0%
39.4%
23.0%
Food Allergens
**
31.0%
**
39.0%
**
28.0%
**
11.0%
**
14.0%
**
33.0%
**
50.0%
**
39.0%

*United

Armentia
(2017)
Spain
n = 129

Rodrigues
(2014)
Brazil
n = 35

Philpot
(2016)
Aust
n = 75

**

**

**

63.5%
9.3%
71.4%

**

70.0%
2.00%
67.0%

**

**

**

**

**

**

**

22.8%
8.50%
22.8%
34.1%
14.2%
2.80%

27.0%
4.00%
10.0%

**
**
**
**
**

**
**

9.3%

**

**

**

**

0.00%
19.0%
4.00%
**

4Meat

States reports
**Allergen not tested
1Grass (other) –Bermuda grass and/or rye grass
2Tree (other) – each and/or olive
3Dander – cat and/or dog and/or bird

–chicken and/or pork and/or beef
5Nuts –peanuts and/or walnuts and/or
hazelnuts
6Food (other) –vegetables and/or fruits

The goal of this study was two-fold. First, atopic comorbidities and sequela of EoE in Nevada
were examined by means of a hospital utilization database and the most common comorbidities identified
in the state across both pediatric and adult eosinophilic esophagitis patients. Second, this study aimed to
demonstrate if Nevada has unique allergen sensitization patterns given the state’s extreme climate and
health care challenges utilizing an allergy referral clinical dataset for histologically positive EoE pediatric
patients. It is hypothesized that statewide, Nevada EoE patients have distinct differences in comorbid
conditions as compared to EoE patients in other US geographic locations.
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Methods
Records were extracted and filtered to include only Nevada residents. Inclusion criteria for this
study included healthcare records with primary (1) through quaternary (4) EoE diagnosis codes (ICD-9 =
530.13 or ICD-10 = K20.0) from all hospital settings, resulting in a total of 2,298 records. Only primary
through quaternary diagnosis code records were considered “relevant” to the study, as EoE can also be a
comorbidity (Durrani et al., 2018). Each data point represents a hospital record and not an individual
patient in this database. Exclusion criteria included records that did not contain an EoE ICD-9 or ICD-10
code in the primary through quaternary diagnosis codes and patients that lived outside the Nevada state
line.
Furthermore, permission was granted by the University of Nevada, Reno School of Medicine
(UNR SOM) to use a pediatric allergy/immunology clinical skin test dataset. Then derived from pediatric
gastroenterologist referrals to the UNR SOM Allergy Clinic patients less than 18 years of age who had
biopsy proven EoE. The clinical presentation of the patients was known and documented in the dataset.
Skin testing methods were derived from Wong et al. (2012) and were performed with glycerinated
extracts purchased from ALK-Abello (Denmark, EU). Percutaneous skin test utilizing a DermaPik were
performed, a positive control of histamine and negative saline control were placed (Corder & Wilson,
1995). Histamine results of 3 mm or larger were considered an adequate positive control (Wong et al.,
2012). Sensitization was noted with either an aeroallergen or food extract if reaction was at least ½ the
size of the measured histamine and was also larger than then negative control (Wong et al., 2012). This
project was deemed exempt for secondary data analysis by the UNLV Office of Research Integrity
Human Subjects Board due to the de-identified nature of the data.
Statistical Analysis
Descriptive statistics were performed to identify demographics most associated with EoE records
across various characteristics. The results were presented by demographic of interest (all pediatric records
versus all adult records and all male records versus all female records). All variables were categorical
(race, gender, and all-cause diagnosis levels 1 through 4), including age which was grouped into pediatric
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(0-17 years) and adult (18+years) subgroups. Using diagnosis variables “diag 01 – diag 04”,
comorbidities were extracted from and ranked from highest to lowest in occurrence by age and gender.
This allowed for the identification of comorbidities for stratification. Due to numerous and duplicate ICD9 and ICD-10 codes, similar clinical conditions and codes were grouped together for ease of ranking the
comorbidities. Gastritis codes were reduced to include only specified, post-biopsy ICD codes to prevent
over representation of a common “catch-all” clinical code. Lastly, frequencies were calculated for the
clinical sensitization data provided by the UNR SOM to determine which food allergens or aero allergens
were most prevalent.
Results
Population
The initial CHIA database search yielded over 12 million all-cause hospital utilization records
over five years (2013-2017) for the state of Nevada. Data reduction resulted in removal of one repeat
record and one additional record from the database as the zip-code listed indicated a potential data entry
error. The final count after data reduction was 2,196 EoE records across all study years (2013-2017) and
hospital settings. A clinical subset obtained from UNR SOM included 59 cases of histologically
confirmed pediatric EoE patients from both Reno and Las Vegas, Nevada and yielded sensitization results
for >100 potential food and aeroallergens.
Nevada Demographic Results
The mean age of the pediatric population was 10.0 years (median = 11 years, standard error of the
mean (SE) = 0.175); the adult population the mean age was 46.2 (median = 45 years, SE = 0.416) (Table
5). Mean age among female EoE patients was 39.2 (median = 40.5 years, SE = 0.747), and males was
29.8 (median = 27 years, SE = 0.565) (Table 5). Caucasian was the predominant race among all EoE
records and Native American/Alaskan was the least represented (<1.0% of the dataset) (Table 5). There
was less male representation among the pediatric than the adult records; male n = 594 (27.05%) and n =
804 (36.61%), respectively (Table 5).
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Table 5. Demographic Analysis Among All Positive EoE Records in Nevada.

Age (mean/SE*)
Race
White/Caucasian
Asian/Pacific Islander
Black/African American
Hispanic
Native American/Alaskan
Other
Unknown/Missing
Gender
Female
Male

Pediatric (0-17)
n = 785
10 (0.18)
n (%)
526 (23.9%)
22 (1.00%)
66 (3.01%)
66 (3.01%)
1 (0.05%)
43 (1.96%)
61 (2.78%)
191 (8.70%)
594 (27.1%)

Adult (18+)
n = 1,411
46.2 (0.42)
n (%)
834 (37.9%)
28 (1.28%)
33 (1.50%)
58 (2.64%)
2 (0.09%)
21 (0.96%)
435 (19.8%)
607 (27.6%)
804 (36.6%)

Female
n = 798
39.2 (0.75)
n (%)
504 (63.2%)
14 (1.75%)
24 (3.00%)
40 (5.01%)
1 (0.12%)
13 (1.63%)
202 (25.3%)

Male
n = 1,398
29.8 (0.57)
n (%)
856 (61.2%)
36 (2.58%)
75 (5.36%)
84 (6.00%)
2 (0.14%)
51 (3.65%)
294 (21.4%)

*Standard Error (SE)

Comorbidities Associated with EoE in Nevada
In a thorough literature review, EoE was commonly diagnosed along with atopic diseases,
therefore, atopic comorbidities were extracted from published literature. Common published EoE
comorbidities are presented in Table 6. While not directly comparable to the results table, it should be
noted that the CHIA dataset listed asthma as a comorbidity in 11.2% of EoE records, followed by food
allergies (2.19%), and atopic dermatitis/eczema (1.55%). Allergic rhinitis and allergic conjunctivitis were
listed as comorbidities in <1.0% of records. While not directly comparable to the published literature, it
appears that the atopic comorbidities from positive EoE patient records in Nevada was far lower than
many other allergy referral clinic studies performed in the United States and abroad.
Table 6. Summary of the Most Reported Atopic Disease Comorbidities Associated with EoE Nationally
and Abroad.
Sugnanam Rodrigues Moawad
2017
2014
2010
Aust.
Brazil
MD*
Loc.
60.0%
11.0%
Asthma 66.7%
**
**
13.4%
Food
1
55.6%
42.8%
6.29%
AD
93.3%
74.2%
33.9%
AR2
**
**
**
AC3
Ref.

*United

States reports
**Comorbidity not reported
1Atopic Dermatitis/eczema

Mansoor
2016
OH*
29.2%
20.3%
26.3%
35.1%

Fahey
2017
NY*
**

**

**

**
**

36.0%

2Allergic

Kagalwalla
2017
IL*
28.2%
31.1%
41.0%
58.9%
17.9%

Rhinitis
3Allergic Conjunctivitis
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Mohammad Letner
2017
2017
OH*
MA*
39.0%
45.0%
**
57.9%
46.1%
27.4%
61.9%
70.0%
**

**

Esophageal obstructions and esophageal strictures/stenoses ranked highest among the adult, male,
and female demographic groups in Nevada (23.87%, 13.16%, and 16.45%, respectively) (Table 7). Hiatal
hernias were also present, at 10.1% in the adult, 7.52% in the female, and 6.22% in the male subgroups
(Table 7). A common comorbidity in males included asthma (7.87%). Other comorbidities were similar
among the female and male demographic subgroups and included diseases of the stomach, duodenum,
and intestine (8.15% and 11.9%, respectively), atrophic gastritis (4.26% and 4.8% (not shown),
respectively), and gastroesophageal reflux diseases (5.51% and 8.66%, respectively) (Table 7). The top
comorbidity for pediatric records was asthma (13.4%), followed closely by diseases of the stomach,
duodenum, and intestine (7.26%) (Table 4). Various food allergies (7.01%) were the third most common
comorbidity listed. Pediatric patients also exhibited diseases of the stomach, duodenum and intestine,
hiatal hernia, atrophic gastritis, and GERD (Table 7).

Table 7. Comorbid Conditions and Sequela of EoE by Age and Gender.
Comorbidity
Female EoE Positive Records
Esophageal obstruction, Stricture/stenosis of esophagus
Diseases of the Stomach, duodenum, intestine
Hiatal Hernia
Gastroesophageal Reflux Disease (or related)
Atrophic Gastritis
Male EoE Positive Records
Esophageal obstruction, Stricture/stenosis of esophagus
Diseases of the Stomach, duodenum, intestine
Gastroesophageal Reflux Disease (or related)
Asthma
Hiatal Hernia
Adult (18+) EoE Positive Records
Esophageal obstruction, Stricture/stenosis of esophagus
Diseases of the Stomach, duodenum, intestine
Gastroesophageal Reflux Disease (or related)
Hiatal Hernia
Atrophic Gastritis
Pediatrics (0-17) EoE Positive Records
Asthma
Diseases of the Stomach, duodenum, intestine
Listed Allergies
Atrophic Gastritis
Gastroesophageal Reflux Disease (or related)
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n (%)
150 (18.8%)
65 (8.15%)
60 (7.52%)
44 (5.51%)
34 (4.26%)
277 (19.8%)
166 (11.9%)
121 (8.66%)
110 (7.87%)
84 (6.22%)
416 (29.5%)
163 (11.5%)
149 (10.6%)
142 (10.1%)
48 (3.40%)
105 (13.4%)
57 (7.26%)
55 (7.01%)
40 (5.10%)
29 (3.69%)

Clinical Allergy Sensitization Data
The clinical subset contained pollen and food sensitization results from EoE patients in one clinic
located within the University of Nevada, Reno School of Medicine. Overall, 49 foods and 51
aeroallergens were tested for 59 pediatric patients. In total, 76.3% of patients demonstrated food allergy
sensitization to at least one food. Of EoE patients with food allergy sensitization the food group with the
highest rate of sensitization was nut and seed (n = 34, 57.63%); followed by dairy (n = 23, 38.98%),
seafood (n = 23, 38.98%), vegetables (n = 18, 30.51%), and grains (n = 13, 22.03%) (Table 8). Nearly
95% of patients demonstrated aeroallergen sensitization. Over 80% of the positive EoE pediatric patients
had sensitization to weed pollen (n = 50, 84.75%) and tree pollen (n = 49, 83.05%); over 70% to grass
pollen (n = 45, 76.27%), and animal dander (n = 43, 72.88%) (Table 5). Overall, aeroallergen
sensitization from weed and tree were >20% higher in pediatric patients than the highest observed food
allergen nuts/seeds (n = 34, 57.63%) (Table 8). Skin prick results from all 59 patients are presented below
(Table 8). Overall, among the 59 pediatric patients tested there were 1,495 total positive reactions
between food allergens and aeroallergens. Only 17.06% (n = 255) of the positive reactions were from
food allergens and 82.94% (n = 1,240) of the positive reactions were from the aeroallergens tested.
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Table 8. Sensitization Results from Histologically Positive EoE Pediatric Patient Skin Prick Tests.
Food Allergens (n (%))
34
57.63%
Nuts/Seeds1
23
38.98%
Dairy2
23
38.98%
Seafood3
18
30.51%
Vegetables4
13
22.03%
Grains5
12
20.33%
Meat6
11
18.64%
Seasonings7
7
11.86%
Fruit8
All Allergens (n = 1,495 total + reactions)
255
17.06%
Food Positive
1,240
82.94%
Aero- Positive

Weed9
Tree10
Grass11
Dander12
Mold13

Aeroallergens (n (%))
50
49
45
43
15

84.75%
83.05%
76.27%
72.88%
25.42%

1Nuts/Seeds

– peanut, cashew, almond, walnut, pecan, hazelnut, pistachio, Brazil nut, coconut, sunflower
seed, sesame seed
2Dairy – egg, milk, soy
3Seafood – cod, oyster, shrimp, crab, flounder, tuna, lobster, clam, salmon, scallops
4
Vegetables – celery, garlic, onion, pea, tomato, carrot, corn, white potato, sweet potato
5Grains – wheat, barley, oat, rice
6Meat – beef, chicken, lamb, pork, turkey
7Seasonings – vanilla, cinnamon, mustard, cocoa
8Fruit – avocado, orange, apple, strawberry, blueberry, banana, pear, peach, apricot, pineapple, cantaloupe
9Weed: pigweed, sagebrush, plantain, dock, ragweed, ragweed-mix, marsh elder, Russian thistle, rabbit bush,
saltbush
10Tree (other) – pecan, juniper, cedar, alder, oak, elm, willow, locust, cottonwood, birch, maple, privet, aspen,
olive, sycamore, pine, walnut, sweet gum, mulberry, ash, ailanthus
11Grass (other) – timothy, brome, bermuda, saltgrass, johnson, alfalfa
12Dander – horse, hamster, feather, cat, dog, cattle, mouse, cockroach
13Mold – Alternaria, Aspergillum, Penicillium, Cladosporium, Drechslera, Curvularia, moldmix2, Smuts
(Reported as percentage of total cases with at least one positive result; n = 59).

Discussion
Eosinophilic esophagitis studies in the state of Nevada are limited. There are several published
studies nationally and internationally; yet this is the first study to our knowledge examining EoE
comorbidities in the state of Nevada. The results for this study are novel as the reported comorbidities and
allergens are significantly different than those reported in the literature. Pediatric allergy sensitization data
suggest that those with atopic comorbidities may have more aeroallergen induced disease than food
allergy associated disease than previously reported.
Over 30% of the CHIA adult EoE population had reported esophageal obstruction, stenosis, or
stricture of the esophagus. These results indicate that EoE patients in Nevada are seen in the later stages
of the illness where cost is high and when damage is potentially irreparable. A study in 2016 examined a
cohort EoE positive patients and identified that delay in EoE diagnosis was associated with stricture
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formation (Lipka, Kumar, & Richter, 2016). A significant difference in mean time of diagnosis was
observed in positive EoE patients with less than 10mm esophageal diameter when compared to patients
with a diameter greater than 10mm (Lipka et al., 2016). In another study, esophageal function tests were
examined and researchers concluded that function of the lower esophageal sphincter and muscles of the
esophagus decrease with longer EoE disease duration (van Rhijn, Oors, Smout, & Bredenoord, 2014).
This study reports that the longer the disease duration, the prevalence of abnormal esophageal functioning
increases from 36% in those with a disease duration between 0-5 years to 83% in those with disease
duration over 16 years (van Rhijn et al., 2014). Additionally, routine EoE visits, as reported in a study by
Jensen et al. (2015), determined that patients with EoE cost over $3,000 per visit compared to $1,000 for
gender and age matched controls at the same hospital (p<0.001) (Jensen et al., 2015). According to the
study, a significant amount of the cost increase was due to the increased number of endoscopies and
pharmacy claims, particularly once EoE progressed to later stages as seen in the Nevada population
(Jensen et al., 2015).
Over 10% of all adult EoE records in Nevada listed hiatal hernia as comorbid. Both Barrett’s
esophagus, a serious complication of GERD, and hiatal hernias have been loosely associated with EoE in
several studies (AJ., 1995; Cherian, Smith, & Forbes, 2006; Maradey-Romero, Prakash, Lewis,
Perzynski, & Fass, 2015; Schoepfer et al., 2013; Takashima S, Tanaka F, Otani K, Hosomi S, Nagami Y,
Kamata N, Taira K, Yamagami H, Tanigawa T, Fukumoto S, Watanabe T, 2019). One study from
Minnesota highlighted that hiatal hernias likely contribute to the development of Barrett’s esophagus
(AJ., 1995). A 2019 study from Japan argued that while Barrett’s esophagus was negatively associated
with EoE, hiatal hernias were observed in over 20% of the EoE population (Takashima S, Tanaka F,
Otani K, Hosomi S, Nagami Y, Kamata N, Taira K, Yamagami H, Tanigawa T, Fukumoto S, Watanabe
T, 2019). Based on published literature, an association between EoE, hiatal hernia, and Barrett’s
esophagus may exist, particularly in the Nevadan population where Barrett’s esophagus codes were
observed among 2.09% (n = 46) of positive EoE records.
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The only atopic comorbidities present in the CHIA dataset appeared in the male and pediatric
subgroups. In males, asthma was reported in nearly 8.0% and approximately 13% in pediatrics, lower
than reported state averages (10.4% in adults and 23.0% in pediatrics). Australia, Brazil, and Ohio both
report high asthma rates among EoE patients (Mohammad et al., 2017; Rodrigues Mariano De Almeida
Rezende et al., 2014; Sugnanam et al., 2007). When the diagnosis code search was expanded (diagnosis
position 05 – 37), allergic rhinitis was observed in <1% of the EoE population in Nevada (n = 2,196). In
Australia, EoE is often seen in conjunction with allergic rhinitis (93.33% of patients), followed by
asthma, atopic eczema, and anaphylaxis (Sugnanam et al., 2007). Brazil reports allergic rhinitis as the
most common comorbidity, identified in 74.2% of EoE cases, with asthma and atopic dermatitis
following closely behind (Rodrigues Mariano De Almeida Rezende et al., 2014). In the United States,
Massachusetts, Ohio, and New York all reported allergic rhinitis as the most common comorbidity (70%,
61.9%, and 36%, respectively), followed by food allergies, asthma, and atopic dermatitis (Fahey et al.,
2017; Letner et al., 2018; Mohammad et al., 2017). Illinois also specified allergic rhinitis as the most
common comorbidity among EoE patients (58.9% of cases), followed by eczema, food allergies, asthma,
and allergic conjunctivitis (Kagalwalla et al., 2017). Compared with the published literature worldwide,
the atopic comorbidities identified in Nevada EoE records were much lower than expected.
Clinical Subset
The clinical subset highlighted several notable distinct allergens not found in other regions. In
three of the largest EoE population studies, authors claim that food allergies were the causative agent of
the disease in over 90% of patients (Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, 1995;
Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E, Flick J, Kelly J, BrownWhitehorn T, Mamula P, Markowitz JE.Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas
M, Semeao E, Flick J, Kelly J, Brown-Whitehorn T, Mamula P, 2005; Markowitz JE, Spergel JM,
Ruchelli E, 2003). In the clinical subset of Nevada patients, weed, tree, and grass sensitization were
dominantly identified. Overall, positive skin prick tests for food allergens accounted for 17.06% of the
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total positive skin test results whereas positive aeroallergen results were found in over 80% of the
pediatric EoE patients.
Within the food sensitized patient population the percent of these patients having specific food
group positive skin test results were similar to or lower, than other published studies. The highest food
allergen group identified in Nevada among positive EoE patients was nuts/seeds (57.63%). Other studies
report nut allergens in EoE patients between 4% (Australia) and 51% (Wisconsin, USA) (Philpott et al.,
2016; Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). Dairy (38.98%) and seafood (38.98%) were among
the other food allergens identified in Nevada. In other studies, dairy ranges from 4.00% (Australia) and
39.0% (New York, USA) and seafood ranges from 0.00% (Australia) to only 14.0% (New York, USA) in
EoE patients (Fahey et al., 2017; Philpott et al., 2016).
Weed sensitization in Nevada is reported in nearly 85% of EoE patients. The highest identified
weed allergens in the literature exist in Wisconsin and Ohio, where weed allergens are only identified in
40% and 60% of cases, respectively (Slack et al., 2013; Xiwei Zheng, Cong Bi, Marissa Brooks, 2015).
Tree pollen sensitization are found in 83% of EoE patients in our Nevada clinical subset. In the literature,
tree pollen allergens in the EoE population range from 2.0% in Australia to 70% in Wisconsin (Philpott et
al., 2016; Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). Grass sensitization in Nevada were identified in
over 75% of the pediatric patients tested; grass sensitization is reported in 17.0% of individuals diagnosed
with EoE in New York, and close to 70% of EoE patients in Australia (Fahey et al., 2017; Philpott et al.,
2016). Animal dander was reported in 72.88% of the EoE Nevadan population, but in only 66.0% in
Wisconsin, 39.4% in Ohio, and 23.0% in New York (Fahey et al., 2017; Slack et al., 2013; Xiwei Zheng,
Cong Bi, Marissa Brooks, 2015). Globally, the percent of patients demonstrating aeroallergen
sensitization from Nevada are significantly higher than other reported studies. This suggests that a
geographic etiology may play a role in our findings as most comparable studies are based in the eastern
segment of the United States.
There are several unique geographical factors in Nevada that can explain the significant increase
in aeroallergen sensitization seen in the pediatric EoE population. In a study examining a cohort of
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children, Wong et al. (2012) identified that over 50% of children aged between 6-7 were sensitized to at
least one aeroallergen in the state of Nevada (Wong et al., 2012). Due to the decreased rain and increased
wind in the area known as the Great Basin, aeroallergens have significantly increased over the years
(Wong et al., 2012). Another study reported that winds across the Great Basin cause pollen variation
within individual cities in Nevada. Patel et al. (2018) found that variation in pollen concentration occurred
in microenvironments across five different locations in the city of Las Vegas alone (Patel et al., 2018).
The study also found significant variations in pollen concentrations and compositions across the city
(Patel et al., 2018). Tree was the greatest contributor to the average pollen concentrations, followed by
weed, and grass (Patel et al., 2018). These increased pollen rates may impact pediatric EoE patients more
than any of the food allergens tested. Nevada gets the least amount of rain annually than any other state in
the United States. Unlike other states in the Northeastern or Midwestern US, the lack of rain allows for
the presence of accumulated pollen (Lilly, 2016; Patel et al., 2018). Without rain, pollen accumulates and
becomes a perennial exposure, which has been previously reported in Nevada (Wong et al., 2012). The
climate in Nevada could account for the significant differences in allergens observed in this EoE
population, particularly when compared to the Midwestern and Eastern seaboard regions of the United
States; where rain and snow are plentiful year-round.
Strengths and Limitations
One limitation for this study includes the inability to calculate true patient level comorbidities; as
the individual level for analyses is the patient record and not the individual. This is particularly true for
the esophageal obstruction, stricture, and stenosis ICD code used. Some records are likely repeat visits, as
patients with EoE tend to be seen multiple times per year due to strictures or stenoses. Repeat visits
cannot be accounted for in the data making it difficult to determine how many individual patients are truly
represented within the dataset. Finally, there are less than 30 allergists listed on the American Academy of
Allergy, Asthma, & Immunology (AAAAI) website for the state of Nevada; this indicates that there are
not enough specialty allergists in the state making EoE difficult to capture or diagnose which may be
contributing to the inconsistency in treatment by provider and region.
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A major strength of this study is the large population size of EoE records gathered from the CHIA
database across multiple years; as well as the large number of conditions identified with diagnosis codes.
Study power was sufficient to assess a condition that may otherwise have been difficult to achieve an
adequate sample size. As these are healthcare utilization data with diagnosis codes, these data are
typically more accurate than the self-reported data found in some other studies. Additionally, the clinical
subset provided by UNR SOM allowed for a clinical and parallel assessment among a unique population.
This data shows a significant burden of disease for EoE patients overall. This clinical dataset was referred
by a GI subspecialist to an allergy subspecialist, making it very unique.
Conclusion
While the scientific knowledge of EoE continues to grow, more studies are required across larger
geographic regions. Our clinical allergy sensitization dataset indicated that sensitization to aeroallergens
in EoE patients far exceed the presence of food sensitization. These patterns conflict with most studies,
making this novel information for providers of EoE patients, especially in climates like Nevada.
In Nevada irreversible sequela, obstructions/stenosis/strictures were seen in 30% of adult patients
and less than 1% of pediatric patients had this, none of which were part of our clinical subset. High rates
in adults have been shown to be due to delayed diagnosis. Low rates in children may be due to early
diagnosis of these patients by allergists and pediatric gastroenterologists in Nevada. Furthermore,
adequate care for pediatrics through the use of both GI and allergy specialists may help prevent disease
progression. Both of which suspect the disease and may understand the importance of aeroallergen
importance. However, in the adult population this may not be the case. Given the large number of patients
with aeroallergen sensitizations from the referral clinical database, we suspect that this comorbidity is
being under diagnosed state wide. More literature in similar climates with evidence similar to our
experience may increase awareness of these being comorbid conditions and lead to earlier diagnosis and
result in less severe sequela of the disease.
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Chapter 4: Impact of Eosinophilic Esophagitis in Nevada

Abstract
The cost and quality of life impact of the rare disease eosinophilic esophagitis (EoE) are seldom
discussed in the literature. This study examines the cost of EoE in the state of Nevada and puts into
context the severity of the illness when compared to similar, more well-known chronic immune
inflammatory conditions. Several significant demographic factors influenced the overall cost of EoE in
Nevada, including those in the pediatric age group, males, and those living in the Southern region
(p<0.001). Using Mann Whitney U, when cost is compared to Crohn’s disease and Celiac disease, EoE is
significantly more expensive for pediatric records, those living in the southern region, males, and those
seeking medical advice from outpatient therapy centers (p<0.001). A binary logistic regression model
revealed that age, gender, region, and hospital setting were all associated with having a positive EoE
versus Crohn’s disease record (p<0.001). Additionally, a second model revealed that age, gender, and
hospital setting were all associated with having a positive EoE record versus a Celiac disease record
(p<0.001). Here, were present data showing that EoE is as significant as other chronic inflammatory
illnesses in the state of Nevada. Education for this disease should be drastically improved as the
prevalence continues to rise.
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Introduction
Eosinophilic esophagitis (EoE) has been described worldwide since before 1980, however, this
disease was only recently identified by the United States International Classification of Diseases (ICD) in
1998 (James & Assa’ad, 2018). According to the American Partnership for Eosinophilic Disorders
(APFED), coding for EoE had previously relied on specific symptomology for already known conditions,
including: dysphagia, achalasia, and gastroesophageal reflux disease (GERD) (James & Assa’ad, 2018).
While this disease is now more recognizable, concern in gastroenterology, allergy, and immunology
communities continues to grow as new information surfaces (James & Assa’ad, 2018). With this disease
on the rise alongside atopic diseases, few studies examine the overall cost of this EoE, particularly in
comparison to similar chronic immune or inflammatory conditions (Davis, 2018).
Jensen et al. (2015), to our knowledge, is the only published study that has attempted to estimate
the cost of EoE in the United States (Jensen et al., 2015). This study examined US claims data and
identified 8,135 cases of EoE (Jensen et al., 2015). In a matched study with 32,540 controls for
comparison, Jensen et al. calculated the median annual cost per EoE record at $3,304.00; triple the total
cost of $1,001.00 calculated per gender and age matched controls (p < 0.001) (Jensen et al., 2015). Costs
included additional outpatient visits, endoscopies, and pharmacy claims, all related to an EoE diagnosis
(Jensen et al., 2015). Jensen et al. (2015) estimated the overall annual cost of EoE in the United States as
upwards of $1.4 billion, which is an astounding overall cost for a disease that was formally classified just
over two decades ago (Jensen et al., 2015). The study gave a broad overview of EoE cost in the United
States; however, did not provide a differentiation of cost by demographic subgroup or provide context to
the overall cost exhibited by the illness.
Economic burden is difficult to conceptualize for a rare disease like EoE. This study sought to
add to the current literature by examining the overall cost of EoE by demographic subgroup in the state of
Nevada using a large hospital utilization database. By examining the cost associated with age, gender,
region, and hospital setting, this study aimed to describe the significant differences in treatment cost and
options utilized in the state by demographic. Additionally, the overall cost of EoE records was compared
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with two similar and well-categorized chronic inflammatory diseases, Crohn’s disease (CD) and Celiac
disease (CeD), to illustrate the relative cost burden of EoE in Nevada. Logistic regression models were
utilized to identify key factors that set EoE apart from CD and CeD to stress that EoE, while considered
rare, is just as costly and dangerous.
Methods
Population
Records from the database were extracted and filtered to include only Nevada residents. Inclusion
criteria for this study included healthcare records with primary (1) through quaternary (4) EoE diagnosis
codes (ICD-9 = 530.13 or ICD-10 = K20.0) from all hospital settings. Exclusion criteria included the
presence of a concurrent or comorbid CD or CeD ICD codes with EoE, resulting in a total of 2,190
positive EoE records across all study years (2013-2017) and hospital settings. It should be noted that
record was the individual level of analyses and not the actual patient.
Several factors were involved with the selection of the comparator illnesses, CD and CeD, for the
cost comparison. First, the relationship between EoE and atopic diseases is well documented in the
literature, therefore an allergic component was included (Benninger, Strohl, Holy, Hanick, & Bryson,
2017). Secondly, the diseases were to be clinically similar as well as require equivalent diagnostic
methods. All three diseases presented here are chronic immune mediated illnesses with documented
relationships to atopy (Benninger et al., 2017; Katsanos, Zinovieva, Lambri, & Tsianos, 2011; Leslie,
Mews, Charles, & Ravikumara, 2010; Stewart, Shaffer, Urbanski, Beck, & Storr, 2013). Specifically,
Eosinophilic esophagitis is an immune-mediated disease characterized by esophageal or upper
gastrointestinal symptomology, diagnosed via endoscopy and pathological findings, and treated using
dietary restrictions or high-dose proton pump inhibitors (Leslie et al., 2010). Celiac disease is an immunemediated illness characterized by intolerance or allergy to dietary gluten causing significant damage to the
intestine, and treated using dietary restrictions or anti-inflammatory medication (Leslie et al., 2010;
Stewart et al., 2013). Crohn’s disease is an inflammatory bowel disease diagnosed via colonoscopy and
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treated short-term using corticosteroids or immune system suppressors and long-term using dietary
restrictions (Katsanos et al., 2011).
Statistical Analysis
The total associated service costs for EoE were extracted and analyzed by demographic subgroup:
age (pediatric (0-17) versus adult (18+)), gender (male versus female), and region (North versus South).
Once extracted, the median cost per demographic subgroup was assessed. Due to the non-normal
distribution, the Mann Whitney U test was performed to identify significance in cost within subgroups.
All demographic subgroups with EoE records demonstrated significant differences (p < 0.05). Therefore,
frequencies of the top ten most prevalent CPT codes recorded were extracted from the database and
compared to identify which ICD codes contributed to the differences in cost.
Positive EoE records were then compared to two additional chronic inflammatory diseases. In
order to compare the cost of EoE to clinically well-categorized chronic inflammatory illnesses, a random
matched selection of 2,190 records of CD (ICD-9 = 555.9, 560.89 or ICD-10 = 50.00) and CeD (ICD-9 =
579.0 or ICD-10 = K90.0) were extracted from the hospital utilization database across the same
timeframe. Due to a small number of extreme outliers, records >99th percentile were removed before the
final analysis, resulting in EoE (n = 2,167), CD (n = 2,168), and CeD (n = 2,168) total records.
Frequencies were calculated for demographic and median cost for each disease, as well as Mann Whitney
U to identify significant differences in cost by demographic subgroup.
Binary logistic regression models were run to determine if demographics were impacted more
significantly by EoE than CD or CeD. Secondary analysis was performed to identify demographic
differences between the diseases of interest in terms of odds ratios. The dependent variable was an EoE
positive record (1) versus a positive CD or CeD record (0). A P-value of less than 0.05 and the 95% CI
were set for statistical significance for all binary logistic regression models. All statistical analyses were
run using R version 3.1.5 (11).
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Results
Nevada EoE Cost Burden
Overall, the cost of EoE in Nevada varied significantly by demographic factors. The median cost
per record for adults ($1,906.00) on average, was less compared with pediatric records ($4,001.00) (p <
0.001) (Table 1). The median cost per male record ($2,532.5) was greater than females ($1,906.00)
(Table 1). Finally, records extracted from the Southern region yielded a median cost of $4,501.00
compared with $1,025.00 per record for the Northern region of the state (p < 0.001) (Table 9).
To identify why the significant differences in cost existed by demographics, CPT codes were
extracted from all positive EoE records and compared by subgroup. The most prevalent CPT code among
all EoE records included esophagogastroduodenoscopy (by age, region, and gender) (Table 9). Among
adults and females, miscellaneous surgical supplies (n = 269, 19.1%; n = 124, 15.7%, respectively),
fentanyl citrate 0.1mg injections (n = 229, 16.3%; n = 120, 15.2%, respectively), and surgical pathology
gross and microscopic examination (n = 163, 11.6%; n = 149, 18.8%, respectively) were the most
prevalent subsequent CPT codes recorded (Table 9). CPT codes identified for the pediatric sub-group
were as follows: surgical pathology gross and microscopic examination (n = 273, 34.5%) was more
prevalent, followed by 10mg propofol injections (n = 233, 29.8%) and special stains with interpretation
and reporting (n = 123, 15.8%) (Table 9). Among male EoE records, the most prevalent reported CPT
codes included surgical pathology gross and microscopic examination (n = 299, 21.4%), followed by
10mg propofol injections (n = 229, 16.4%), and miscellaneous surgical supplies (n = 196, 14.02%) (Table
9). One important difference among EoE records by gender was the presence of the urinalysis procedure
for females (n = 67, 8.46%) but not males (Table 9).
The largest difference in EoE record patterns existed by region of the state. The difference in total
number of positive EoE records between regions was less than 10%, however, the median cost per record
in the Southern region was over 50% higher when compared to the Northern region (p < 0.001). In the
Northern region, miscellaneous surgical supplies (32.3%), fentanyl citrate 0.1mg injections (28.4%), and
venous procedures (15.5%) were among the most prevalent CPT codes recorded (Table 9). However,
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miscellaneous surgical supplies and fentanyl citrate 0.1mg injections in the Southern region of the state
accounted for less than 1%, followed by very low venous procedure rates (3.86%) (Table 9). In the
Southern region, surgical pathology gross and microscopic examination (34.3%), 10mg propofol
injections (25.0%), and special stains with interpretation and reporting (16.0%) comprised the majority of
the CPT codes when compared to the Northern region (Table 9).

Table 9. CPT Codes and Associated Cost Among Positive EoE Records.
n
%
Total Cost
Median Cost Cost/Record
781
35.7%
$3,728,583
$4,001.00
$4,774.11
1409
64.3%
$5,047,355
$1,906.00
$3,582.22
792
36.1%
$2,852,379
$1,906.00
$3,601.49
1398
63.8%
$5,923,559
$2,532.50
$4,237.17
999
45.6%
$1,594,792
$1,025.00
$1,596.39
1191
54.4%
$7,181,146
$4,501.00
$6,029.51
CPT Codes by Demographic in Nevada (n %)
Adult
Pediatric
Male
Female
North
Esophagogastroduodenoscopy 915
288
746
424
734
64.9%
33.0%
53.4%
53.5%
73.5%
Surgical supply miscellaneous
269
61
196
124
323
19.1%
6.53%
14.02%
15.7%
32.3%
Injection, fentanyl citrate, 229
61
175
120
284
0.1 mg 16.3%
7.81%
12.5%
15.2%
28.4%
Surgical path, gross and 163
273
299
149
30
microscopic examination 11.6%
34.9%
21.4%
18.8%
3.00%
Venous Procedures
154
43
119
83
155
10.9%
5.51%
8.51%
10.5%
15.5%
Injection, propofol, 10 mg 64
233
229
64
<1.00%
4.54%
29.8%
16.4%
8.08%
Special stain with 71
123
126
71
<1.00%
interpretation and report 5.04%
15.8%
9.01%
8.96%
Injection, midazolam 113
53
106
66
146
hydrochloride, per 1 mg 8.02%
6.79%
7.58%
8.33%
14.6%
Urinalysis Procedures
26
33
<1.00%
67
<1.00%
1.85%
4.23%
8.46%
Unclassified drugs
82
32
73
52
108
5.82%
4.10%
5.22%
6.57%
10.8%
Demographic
Pediatric (<18 yrs.)
Adult (+18 yrs.)
Female
Male
North
South

*P-value based on Two-Tailed Mann Whitney U (alpha set at 0.05)
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P-value*
<0.001
0.0012

<0.001
South
438
36.8%
<1.00%
<1.00%
409
34.3%
46
3.86%
298
25.0%
191
16.0%
27
2.27%
57
4.79%
<1.00%

Demographic and Cost Comparison: EoE, Crohn’s disease and Celiac disease
When comparing cost of records between conditions, several demographic factors were
significant (p<0.001) for EoE when compared to both CD and CeD; EoE records had a higher
representation of individuals less than 18 years of age, the male gender, and southern region location
(p<0.001) (Table 10). As for hospital setting, the median cost of inpatient and outpatient therapy centers
was also significant between EoE and CD and EoE and CeD (p<0.001) (Table 10). While EoE cost
significantly more in outpatient therapy clinics (p<0.001), CD and CeD each cost significantly more than
EoE in the inpatient (IP) setting (p<0.001) (Table 10).

Table 10. Total CPT Cost by Demographic and Disease Status.
Demographic

Crohn’s Disease (1)
(n = 2,168)
n (%)
Cost*

Age
Pediatric
101 (4.61)
Adult
2089 (95.4)
Region
Northern
938 (42.8)
Southern
1252 (57.2)
Gender
Female
1275 (58.2)
Male
915 (41.8)
Hospital Setting
ASC4
792 (36.2)
ED5
634 (28.9)
IP6
614 (28.0)
THOS7
150 (6.90)

p-val.8

EoE (2)
(n = 2,167)
n (%)
Cost*

p-val.8

Celiac Disease (3)
(n = 2,168)
n (%)
Cost*

$985
$1,506

<0.001
0.63

781 (35.7)
1409 (64.3)

$4,001
$1,906

<0.001
0.47

113 (6.07)
2077 (94.8)

$856
$1,623

$845
$2,538

0.25
<0.001

999 (42.8)
1191 (57.2)

$1,025
$4,501

0.012
<0.001

1024 (46.8)
1166 (53.2)

$1,014
$1,888

$1,500
$1,500

0.57
<0.001

792 (36.2)
1398 (63.8)

$1,906
$2,532

0.01
<0.001

1304 (59.5)
886 (40.5)

$1,600
$1,724

$1,451
$1,219
$10,474
$741

0.04
0.01
<0.001
<0.001

1045 (47.7)
209 (9.54)
122 (5.57)
814 (37.2)

$1,508
$1,371
$6,872
$3,298

0.28
0.04
<0.001
<0.001

1188 (54.2)
577 (26.3)
220 (10.0)
205 (9.40)

$1,600
$1,262
$9,570
$1,686

*Median

Cost per record shown rounded to the nearest dollar amount
frequencies of a random sample of Crohn’s disease records from CHIA.
2Demographic frequencies of a random sample of EoE records from CHIA
3Demographic frequencies of a random sample of Celiac disease records from CHIA
4Ambulatory Surgery Centers
5Emergency Departments
6Inpatinet Clinics
7Outpatient therapy centers
8P-value calculated using Two-sided Mann Whitney U (alpha set at 0.05)
1Demographic

In a final adjusted model, factors associated with having a positive EoE versus CD record were
identified (p < 0.05); younger age (OR = 7.29; 95% CI: 5.73, 9.27; p<0.001), male gender (OR = 1.78,
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95% CI: 1.47, 2.15; p-value < 0.001), region (South) (OR = 1.87, 95% CI: 1.032, 3.39; p-value = 0.039),
and outpatient setting (OR = 1.31, 95% CI: 2.89, 4.73, p-value <0.001) (Table 11). Significant
interactions were found between region * gender as well as region * hospital setting (p<0.001) (Table 11).

Table 11. Factors Associated with a Positive EoE Event versus Crohn’s Disease (CD).
Odds
Demographic
Ratio
Age
Pediatric (<18)
7.29
Adult (18+)
*
Gender
Female
*
Male
1.78
Region
North
*
South
1.87
Hospital Setting
Inpatient
*
Outpatient
3.69
Interaction
Region*Gender
Region*HS
*
Reference Group
1
HS: Hospital Setting
R2: 25.26%

95% CI
Low
High

p-value

5.73
*

9.27
*

p<0.001
*

*
1.47

*
2.15

*
p<0.001

*
1.03

*
3.39

*
0.039

*
2.89

*
4.73

*
p<0.001

1.18
1.99

2.13
3.89

p<0.001
p<0.001

Differences existed between region and diagnosis (p<0.001). As such stratified models by region
were performed (Table 12). In the Northern region the following factors had significantly higher odds of
an EoE event versus a CD event: younger age (OR = 7.17, 95% CI: 4.68, 10.99, p<0.001), male gender
(OR = 1.78, 95% CI: 1.47, 2.16; p<0.001), and outpatient hospital setting (OR = 3.69, 95% CI: 2.88, 4.72;
p<0.001) (Table 12). In the Southern region, the pediatric sub-group had 7.35 times the odds (95% CI:
5.49, 9.83, p<0.001) of having a positive EoE versus a CD event. Additionally, male records (OR = 2.83,
95% CI: 2.27, 3.53; p<0.001) as well as those from the outpatient hospital setting (OR = 10.29; 95% CI:
8.24, 12.87; p<0.001) demonstrated significantly higher odds of an EoE versus a CD event (Table 2).
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Table 12. Factors Associated with a Positive EoE Event Stratified by Region.
OR
Age
Pediatric (<18)
Adult (18+)
Gender
Female
Male
Hospital Setting
Inpatient
Outpatient

Northern
95% CI
P-value

Southern
95% CI

OR

P-value

7.17
*

4.68, 10.99
*

<0.001
*

7.35
*

5.49, 9.83
*

<0.001
*

*
1.78

*
1.47, 2.16

*
<0.001

*
2.83

*
2.27, 3.53

*
<0.001

*
3.69

*
2.88, 4.72

*
<0.001

*
10.29

*
8.24, 12.87

*
<0.001

*Reference group
Adjusted R2 North: 10.52%
Adjusted R2 South: 36.99%

Additionally, a final model was generated in order to determine the odds of having an EoE versus
CeD code among records. Factors included age, gender, and hospital setting (p<0.001 for all factors). No
interaction effects were identified in this model (p>0.05) (Table 13). The following factors were
associated with having a positive EoE versus CeD record: younger age (OR = 8.59, 95% CI: 6.93, 10.7;
p<0.001), male gender (OR = 2.11, 95% CI: 1.85, 2.42; p-value < 0.001), and records from the outpatient
setting (OR = 2.91, 95% CI: 2.48, 3.42, p-value <0.001) (Table 13).

Table 13. Factors Associated with a Positive EoE Event versus Celiac disease (CeD).
Demographic
Age
Pediatric (<18)
Adult (18+)
Gender
Female
Male
Hospital Setting
Inpatient
Outpatient
R2: 16.69%

95% CI
Low
High

Odds Ratio

p-value

8.59
*

6.93
*

10.7
*

p<0.001
*

*
2.11

*
1.85

*
2.42

*
p<0.001

*
2.91

*
2.48

*
3.42

*
p<0.001

Discussion
Patients diagnosed with a rare illness face significant health disparities compared to those with
well-documented conditions. It can often be difficult for individuals with a rare disease to find reliable
44

information and care for their illness. The data presented here suggest this scenario for EoE patients in the
state of Nevada.
Pediatric EoE records extracted cost significantly more per record (n = 781; $4774.11) that of the
adult records extracted ($3,582.22) but was 45% smaller in terms of sample size (n = 1,409) (p<0.001).
There could be several reasons for the significant difference in cost observed. One hypothesis includes the
high prevalence of atopic illness in children in the state of Nevada (Moawad et al., 2010). Given the close
relationship of EoE and atopy, the rise in pollen sensitizations in Nevada could be a significant factor for
the increased cost to treat EoE in this population. Wong et al. identified that among the 2 to 7-year-old
age group, over 50% of the population observed (n = 123) were sensitized to at least one allergen. A
second hypothesis is that increased risk is involved in children presenting with EoE and will therefore be
more costly for parents (Kavitt, Penson, & Vaezi, 2014). Kavitt et al. (2018) performed a cost analysis of
various EoE treatments on positive EoE patients of all age groups (Kavitt et al., 2014). The study
proposed that swallowed fluticasone should be used prior to esophageal dilation if the patient continues to
be symptomatic post proton-pump inhibitor (PPI) therapy (Kavitt et al., 2014). However, among the top
ten CPT codes extracted from Nevada hospital data, 64.9% of adults and 33.0% of pediatric records
underwent an endoscopy, but only 5.8% of adult and 4.1% of pediatric records had a code for receiving
post-surgical medication; indicating that a lack of education may be driving treatment options in Nevada.
The difference in median cost per record was also significant by gender (p<0.001). Published
studies indicate that males are significantly more likely than females to receive an EoE diagnosis, which
explains the high cost identified in the male records extracted (Dellon, 2014; Dellon & E.S., 2012;
Dellon, Erichsen, et al., 2015). However, males were far less likely than females to have a urinalysis
procedure code in their records. This is an interesting finding and once again points to a lack of
knowledge regarding EoE in the state of Nevada. While there are several clinical trials seeking enrollment
for metabolites associated with EoE via urinary analysis, to our knowledge, no such results have been
published in the literature (Gourley, 2013; The University of Texas Health Science Center Houston,
2018).
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Finally, the total cost per record identified in the Southern region (n = 1,191; $6,029.51) was over
three and a half times that of the Northern region (n = 999; $1,596.39); even though the sample size of
records identified only differed by ~10% between regions (p<0.001). The CPT codes recorded were also
different by region. For example, records from the Northern region documented far more endoscopies
performed than the Southern region and therefore reported higher rates of fentanyl citrate, unclassified
drugs, and miscellaneous surgical supplies. However, in the Southern region, propofol injections were
much higher, as well as pathology strains, interpretations, & reports, and urinalysis. These results indicate
that treatments or diagnostic procedures in the Northern and Southern regions of the state differ
significantly in terms of EoE. This is also reflected in the significant differences in cost exhibited by the
two regions. While a difference in cost is expected between regions, the total number of EoE records
extracted from the Southern region of Nevada versus the Northern region does not account for the large
difference in cost.
Demographic and Cost Comparison across Conditions in Nevada
In an attempt to rank EoE cost burden relative to related but more well-established conditions,
EoE was compared to CD and CeD. Several demographic factors were significantly different across
conditions (p<0.001). Additionally, several demographic factors exhibited increased odds of EoE versus
CD or CeD.
It is documented that Crohn’s disease and EoE have several commonalities including the
epidemiologic trends in Western cultures, potential genetic risk of inheritance, and the use of a
combination of drug and endoscopic treatments (Molina-Infante, Schoepfer, Lucendo, & Dellon, 2017).
In this study, the cost of adult records, female records, those from the Northern region, and certain setting
types was similar between EoE and CD. However, the cost between these two diseases differed
significantly among records from the pediatric subgroup, those from the Southern region, of male gender,
and outpatient therapy settings (p<0.001). The pediatric subgroup was less represented in the CD records
than EoE records; yet the cost for pediatric EoE records was significantly higher per record for EoE than
for CD (p<0.001). Also in the final model the odds were higher among the pediatric subgroup of having a
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positive EoE diagnosis versus a positive CD diagnosis. EoE records extracted from the Southern region (n
= 1191, 57.2%) and those of male gender (n = 1398, 63.8%) showed a similar trend with the median cost
of EoE records significantly higher than that of CD records (p<0.001). Male records as well as those
extracted from the Southern region had higher odds of a positive EoE diagnosis than a CD diagnosis.
Finally, records from a therapy outpatient center setting were more likely to have a positive EoE event
than a CD event as well as being significantly more expensive (p<0.001). However, records from CD (n =
614, 28.0%) had a higher representation in the inpatient clinic than EoE (n = 122, 5.57%) and were
therefore significantly more expensive (p<0.001). Significant differences also existed by region, as shown
in the stratified interaction model. Significant differences existed between the Northern and Southern
regions across several demographics. Records that were younger in age, of male gender, and from
outpatient clinics all had higher odds of a positive EoE event versus a CD event when examined by
region.
The second disease considered relative to EoE was Celiac disease. Several studies indicate that
EoE and CeD may have an association (Hommeida et al., 2017; Pellicano, De Angelis, Ribaldone,
Fagoonee, & Astegiano, 2013). The same trend occurred in CeD as did in CD when compared to EoE.
The median cost for records among adults, from the Northern region, among females, from ambulatory
surgery centers, and from the emergency department were similar between EoE and CeD (p>0.05).
However, the median cost among the younger age group, Southern region, males, and outpatient therapy
centers were significantly more expensive across the EoE records than CeD records. Furthermore,
significant factors associated with having an EoE event versus a CeD event included: younger age, male
gender and outpatient hospital setting (p<0.001). It should also be noted that records from CeD (n = 220,
10.0%) had a higher representation from the inpatient setting than EoE (n = 122, 5.57%) and was
therefore significantly more expensive (p<0.001).
While few studies exist that compare these three conditions, one study highlights the similarities
and potential treatment options between them (Molina-Infante et al., 2017). Molina-Infante et al. (2017)
proposed improving biological disease activity and dietary therapy for patients with chronic inflammatory
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conditions such as EoE and Crohn’s disease through persistent evaluation and treatment by physicians
(Molina-Infante et al., 2017). Moreover, the authors agree that long-term diligence in dietary restrictions
and close monitoring of patients reduces symptoms and inflammation in these patients, thereby improving
overall quality of life (Molina-Infante et al., 2017). As of this writing, there is no approved biologic
therapy for EoE.
There are several studies that show the impact of EoE on quality of life, which cannot be
overlooked (Dellon & E.S., 2012; Mukkada et al., 2018; Stern, Taft, Zalewski, Gonsalves, & Hirano,
2018). Quality of life in terms of emotional and financial burden are often discussed in EoE literature.
The restrictive diet that often accompanies EoE and induced anxiety from choking on food due to stricture
or stenosis of the esophagus, have all been documented emotional quality of life limitations (Dellon,
2014; Stern et al., 2018). Additionally, if impaction occurs, emergency services and an emergency
endoscopy is often the response, which is a significant financial and emotional burden (Stern et al., 2018).
This paper presents results that show the cost of this disease per record is just as high as other, more wellknown chronic inflammatory diseases. Males and younger patients are more prevalent in the EoE
community, whereas females and older patients are more prevalent in the CD and CeD communities. By
recognizing that this illness is more prevalent and clinically severe than once proposed, particularly in
states like Nevada, the quality of life of EoE patients can be greatly improved and the costs reduced.
Strengths and Weaknesses
One limitation for this study includes the inability to calculate true disease prevalence rates from
the hospital utilization database; as the individual level for analyses is the patient record and not the
individual. This was why the calculations for cost were done per visit rather than per patient. Repeat visits
cannot be accounted for in the data making it difficult to determine how many individual patients are truly
represented within the dataset. Another limitation includes the lack of specialty allergists in Nevada,
making EoE difficult to capture or diagnose. This further supports the differences seen in treatment and
diagnosis options between the Northern and Southern regions of the state.
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A major strength of this study is the large population size of EoE, CD, and CeD records gathered
from the CHIA database across multiple years; as well as the large number of CPT codes, cost, and
demographic differences identified. As these are healthcare utilization data with diagnosis codes, these
data are typically more accurate than the self-reported data found in some other studies.
Conclusion
The first goal of this study was to identify the overall cost of EoE in the state of Nevada by
demographics using service charges and CPT codes extracted from a large hospital utilization database.
Additionally, CPT codes were searched and broken down to identify the most common codes used in the
Nevadan population for this illness. Significant differences in cost were identified in age, gender, and
region. Furthermore, CPT codes differed significantly by region, indicating that knowledge about this
disease and treatment is not consistent across the state. Due to the de-identified nature of the data, it is
impossible to identify which region has more repeat visits; or if one region exhibits more severe
symptoms of the disease which could drive up costs. At the time of this writing, only one pediatric
gastroenterologist doctor was identified in the Northern region, which could indicate a lack of “diversity
of care” in the Northern region when compared to the Southern Region. Additionally, the increased
number of allergy specialists in the Southern region more often look for mast cells (as indicated by the
“special stain and interpretation of report” CPT costs) which could be more costly than procedures in the
Northern region. Finally, the differences in healthcare premium and reimbursement by region could be
driving the differences observed. More research is needed to fill these important gaps.
A secondary goal included assessing the cost and impact of EoE records relative to two other
well-known chronic inflammatory conditions, CD and CeD. Significant differences by cost and
demographic status were identified across the three conditions. The initial number of EoE records
extracted was far lower than the total number of CD or CeD records identified in the state. However, the
cost of EoE among several demographic subgroups was substantial. While EoE is considered rare, the
results presented here show that EoE is just as expensive as other chronic diseases examined in Nevada
and affects males as well as pediatric patients more often than CD or CED.
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In conclusion, the records extracted for this study for CD and CeD have a higher female and adult
representation. Whereas for EoE higher odds and cost among male and pediatric records was notable.
When analyzing hospital setting, data for EoE may be viewed as an outpatient disease and therefore
perceived as less severe when compared to other chronic inflammatory diseases. Based on the data
presented here, EoE is just as costly per record as CD and CeD in certain demographic subgroups. The
significant difference in cost and CPT code profile by region suggests that physicians may encounter
complexities when treating this illness when compared to more well-known diseases.
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Chapter 5: Summary, Implications, and Conclusions
5.1 Summary
As of this writing, 2,585 published manuscripts referencing EoE were available on PubMed, of
which, nearly 85% of the articles have been published in the last decade (National Institutes of Health,
2019). This disease is still in its infancy and significantly more research needs to be done to complete the
etiology, therapeutic, and diagnosis gaps that still exist. No studies, to our knowledge, exist that examine
the risk factors, comorbidities, cost, or impact of EoE within the state of Nevada. While some of the
results presented in this dissertation mimic already published information, the results also highlight
several significant and novel features about eosinophilic esophagitis.
It is well-described in the literature that, on average, males are at twice the risk of developing
EoE than females (Dellon & Hirano, 2018). While slightly higher than average, this was the case in
Nevada as well where 63.7% of the records extracted were labeled male and only 36.3% were female.
This disease also afflicts those of Caucasian descent more than any other race, another similar factor
identified in Nevada. Several of the EoE records identified in the CHIA database also exhibited welldocumented comorbidities, including asthma (11.2%), food allergy (2.19%), and eczema (1.55%).
Finally, identification of EoE in the patient setting via endoscopy was also similar, where over 50% of the
total records pulled had a recorded endoscopy and follow-on testing.
Interestingly, the number of records of EoE identified in Nevada were higher than expected (n =
2,190). If the diagnosis for this disease is delayed, as hypothesized in Chapter 4, there is a recurrent need
for emergency endoscopies due to obstruction, which could be driving the record count and cost higher.
Several climate studies note the wet, cooler regions as having higher rates of EoE, however, Nevada is the
opposite, typically dry and warm year-round (Dellon, Jensen, et al., 2015; Hurrell et al., 2012). The
weather in Nevada does however contribute to a longer, more perennial type pollen season (Wong et al.,
2012). Given the well-documented relationship of EoE and atopic illness, Nevada may be a prime region
to continue studying this disease and could explain the higher than expected record count overall.
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Contrary to the published literature, where atopic illness is predominantly reported, the
comorbidities extracted from the records in Nevada were largely gastric. When all EoE records were
examined, less than 1% contained common comorbid diagnosis codes for allergic rhinitis, allergic
conjunctivitis, or sinusitis (Fahey et al., 2017; Kagalwalla et al., 2017; Letner et al., 2018; Longitudinal et
al., 2015; Moawad et al., 2010; Mohammad et al., 2017; Rodrigues Mariano De Almeida Rezende et al.,
2014; Sugnanam et al., 2007). Comorbidities and sequela extracted from the EoE records in Nevada
included esophageal obstructions, stricture/stenosis of the esophagus, and hiatal hernias across all
demographic subgroups examined. This indicates that physicians are either not recognizing the disease
early enough, or are unsure how to treat it, thereby allowing it to progress.
Also contrary to published literature, sensitization to pollen (over 80% of patients) reigned over
food allergens (less than 20%) in Nevada (Armentia et al., 2018; Fahey et al., 2017; Kagalwalla et al.,
2017; Philpott et al., 2016; Rodrigues Mariano De Almeida Rezende et al., 2014; Slack et al., 2013;
Xiwei Zheng, Cong Bi, Marissa Brooks, 2015). Due to the perennial pollens reported in the state, it is
likely that pollen is not washed away often enough, thus resulting in year-round pollen allergies which
exacerbate EoE symptoms in the population (Patel et al., 2018; Wong et al., 2012). Finally, the cost of
EoE differed significantly by demographic subgroup, particularly when compared to other well-known
chronic inflammatory diseases. Males, younger age, region, and hospital setting were all demographic
factors that set EoE apart from Crohn’s disease and Celiac disease.
5.2 Strengths and Weaknesses
The results in this dissertation were strengthened due to the availability of a statewide hospital
utilization database. The CHIA database covers all hospital settings in Nevada, both inpatient and
outpatient, and provides researchers with over 300 variables per dataset. Variables reported by the various
hospital settings include demographic factors, diagnosis codes, hospital charges, and several important
public health measures. Many of the results gleaned from this dataset can be interpreted with confidence,
particularly the charge per record calculations presented in Chapter 4. If necessary, these calculations can
easily be expanded to calculate the cost of a patient who is seen multiple times a year, or once per year.
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Another strength includes the complementary dataset provided by UNR SOM. The patient data provided
includes one patient to one set of skin prick sensitization test results. This dataset gave us the ability to
calculate sensitization rates for pediatric patients in the state and give us a broad idea of the sensitization
pattern in Nevada. Using these results, we can confidently conclude that pollen sensitization in Nevada
far outweighs that of food, as outlined in Chapter 4.
This study does not go without limitations. A main limitation of the CHIA database is the
inability to calculate prevalence rates. The CHIA data filters through the HIPAA State Officer for Nevada
before distribution to CHIA, ensuring protection and blindness to all personal patient identifiers.
Therefore, it is near impossible to calculate an accurate prevalence rate for Chapter 2 because repeat visits
cannot be accounted for with this data. As mentioned in Chapter 3, some patients with more progressed
illness may visit a gastroenterologist multiple times per year for esophageal stricture or stenoses.
Additionally, because this is clinical data there are several variables missing across all datasets. Marital
status was absent, while race, gender, and age all had several missing values across all records. Between
datasets variables differed as well; variables available across all datasets had to be selected before
combining the final dataset. Finally, human error is always a potential limitation when dealing with data
entry. If a code is entered incorrectly, or into the wrong category, the record will not be pulled during
exploratory data analysis. This is particularly true for high-paced hospitalization areas such as the
emergency and surgery departments.
5.3 Orphan Diseases and the Necessity of Advocacy Groups
Rare diseases, such as EoE, are often referred to as “orphan diseases” due to the lack of funding,
little public awareness, and dependency on advocacy groups for support (No authors listed, 2008). Rare
diseases have several definitions, but on average, affect fewer than 7 out of 10,000 individuals in a
population (Valdez, Grosse, & Khoury, 2016). While the prevalence for rare diseases is low, studies show
that individuals admitted as an inpatient stay three days longer than those admitted under more wellknown conditions (Valdez et al., 2016). It is hypothesized that nearly 80% of the 5,000-8,000 rare
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diseases that exist have an associated genetic component, which could be invaluable given the right
amount of time and funding (Valdez et al., 2016).
The results presented here could help fill several knowledge gaps, as well as advance research
through several advocacy groups that currently work with EoE patients and researchers. Advocacy groups
include: American Partnership for Eosinophilic Disorders (APFED), National Organization for Rare
Disorders (NORD), and American Academy of Allergy, Asthma, & Immunology (AAAAI). Each one of
these groups is a professional organization with specialized physician, caretaker, and patient involvement
that distributes research grants and holds annual meetings to disseminate information about rare diseases
(American Academy of Allergy Asthma & Immunology, 2019; American Partnership for Eosinophilic
Disorders, 2019; National Organization for Rare Disorders, 2019). As a result of the efforts of these
advocacy groups, diagnosis and treatment guidelines have been developed and ICD codes created for
several rare conditions (James & Assa’ad, 2018). Several studies argue that rare diseases, such as EoE,
require advocacy groups to continue driving knowledge forward (Badiu et al., 2017; James & Assa’ad,
2018). Additionally, advocacy groups allow for transparency for patients via readily available knowledge,
as well as drives physician education forward as patients ask more questions about the disease they face
(James & Assa’ad, 2018).
5.4 Public Health Implications and Limitations
There are public health strategies that should be considered based on the results presented here
for EoE and other rare diseases identified in the state of Nevada. Valdez et al. outlines an important public
health operational framework for rare diseases which directly correlates to the main discussion points in
this dissertation (Valdez et al., 2016). This framework first describes the necessity for the assessment of
burden of the disease, including identifying the number of affected individuals, expected health outcomes,
overall quality of life, a health-care use summary, and overall economic cost (Valdez et al., 2016). This
first component was thoroughly discussed in this dissertation in Chapters 2 and 4 for the state of Nevada
in this dissertation. The second component presented by Valdez describes the importance of research on
preventable causes and effective treatments for rare diseases (Valdez et al., 2016). As discussed in
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Chapter 3, it is well documented that EoE and atopy share a relationship, therefore, reducing the exposure
to potential allergens through either medications or food elimination diets would help reduce the overall
patient symptomology and burden. Earlier identification of the disease would reduce the gastric
component identified in Chapter 3 and the overall burden to the patient. Furthermore, while research is
ongoing through the various advocacy groups throughout the country, no EoE research in Nevada is
currently funded.
The third, fourth, and fifth components include: systems for screening and early identification of
rare diseases (3), empowerment and education of people with rare diseases (4), and public policies that
promote access to services and treatments for those diagnosed with rare diseases (5) (Valdez et al., 2016).
These last components described by Valdez et al. are not only limited in the EoE literature, but do not
exist in Nevada. Screening and identification of EoE is limited in Nevada and based largely on physician
knowledge of the disease. As discussed in Chapter 3, many of the EoE diagnoses in the state are made
once the disease has progressed to severe stages. At this point, only one physician is listed on APFED’s
site for the entire state of Nevada that specializes in EoE (APFED, 2019). This severely limits the
likelihood of EoE being diagnosed without prior knowledge or expertise anywhere else in the state.
According to NORD rare disease policy is severely lacking in Nevada (NORD, 2019). For those
suffering from a rare disease, Nevada received a “Fail” grade for out-of-pocket prescription protections
and individual insurance protections (NORD, 2019). The state received a “C” grade for Newborn
screenings, indicating that the state does not screen for all of the recommended uniform screening panel
(RUSP) core conditions (NORD, 2019). Finally, Nevada received an “Incomplete” for the development of
a rare disease advisory council or caucus (NORD, 2019). Given the low grades for rare disease support in
Nevada, combined with the lack of knowledge and limited number of physicians available, changes are
necessary for this population. Importance should be placed on all chronic diseases in the state as well as
availability, access, and knowledge for those suffering from rare diseases.
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5.5 Conclusions
Eosinophilic esophagitis in Nevada is largely overlooked by many physicians. The main goal of
this dissertation was to define the state of EoE in Nevada, identify associated risk factors and
comorbidities, as well put the severity of this disease into context by comparing EoE to other chronic
illnesses. So often rare diseases go unnoticed due to the lack of knowledge or funding. It is our hope that
these results are disseminated to help improve the knowledge gap that exists for EoE in Nevada and helps
shed light on this disease globally.
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Appendix A: EoE CHIA Codebook for analysis in R
ITEM 1.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Hospital Setting
hs
nominal, categorical
no
Hospital setting: asc = ambulatory surgery center, er = outpatient emergency,
ip = inpatient, thos= other outpatient & outpatient surgery

ITEM 2.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Diagnosis Level
diaglvl
ordinal, continuous
yes
EoE is present in diagnosis levels 1 – 33; Only Diag01-04 will be utilized

ITEM 3.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Admit Year
ayear
ordinal, continuous / OR categorical
no
Year of admittance to hospital setting

ITEM 4.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Discharge Year
dischyear
ordinal, continuous / OR categorical
no
Year of discharge

ITEM 5.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

ITEM 6.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Patient Zip Code
patzip
discrete continuous
yes
Zip codes of the patient’s home of record.
0: Unknown/Mis-entered/incorrect (89071 – thos – OO# 1007)

Race
race
nominal categorical
no
Race of the patient
1: Native American or Alaskan
2: Asian or Pacific Islander
3: Black/African American
4: White/Caucasian
5: Hispanic
6: Other/Unknown
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ITEM 7.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:
ITEM 8.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

ITEM 9.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Age in years
age
ordinal continuous
no
Age listed on record upon admission to the setting of interest

Gender of patient
gender
nominal categorical
no
Sex listed on record upon admission to the setting of interest
1: Female
2: Male

Admit Type
atype
nominal categorical
no
Admit type
1: Emergency
2: Urgent
3: Elective
9: Unknown

ITEM 10.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Length of Stay (only in Inpatient dataset)
los
continuous
no
Length of stay (in days) of patients as an inpatient

ITEM 11.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Total Charge
totalcharge
continuous
no
Total cost owed to the hospital setting for services provided

ITEM 12.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Diagnosis Codes 01-04 (ICD-9 or ICD-10 codes)
diag01 – diag4
nominal categorical
yes
List of ICD-9 and ICD-10 diagnosis codes for each record
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ITEM 13.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Procedure Codes (inpatient only; same as ICD-9 or ICD-10 diagnosis codes)
proc01 – proc04
nominal categorical
yes
ICD-9 and ICD-10 procedure codes listed for patients that had procedures done
in the hs.

ITEM 14.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Hospital Revenue Codes
rev01 – rev04
continuous
yes
Revenue codes for hospital billing – defines which part of the hospital billed.

ITEM 15.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Hospital CPT codes (procedure codes)
CPT01 – CPT04
nominal categorical
yes
Labels for the hospital CPT codes/procedure performed

ITEM 16.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Service Charges to patient/insurance company
Srv01-Srv04
continuous
yes
Number of specific times each service was performed.

ITEM 17.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Charges to patient/insurance company
Charge01-Charge04
continuous
yes
Total cost of procedures and medical equipment

ITEM 18.
Variable name:
Variable label:
Variable type:
Missing values:
Description of item:

Original CHIA ID number
CHIAID
nominal
none
The original name of the record in the CHIA datasets.
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